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ABSTRACT 
Highly pathogenic avian influenza (HPAI) H5N1 is an emerging infectious 
virus with a 60% fatality rate in humans. In the United States, a vaccine for H5N1 
has been developed and stockpiled using FDA approved methods for seasonal 
vaccines; however, the H5N1 vaccine was shown to be less immunogenic than 
seasonal vaccines when evaluated in clinical trials. Adjuvants can be used to 
enhance the immune response to antigens. For the studies described herein, a 
lethal mouse model of H5N1 infection was utilized to examine the immune 
response to the H5N1 vaccine with and without the addition of an alum adjuvant, 
and these responses were compared to those induced by a seasonal influenza 
vaccine. Mice that received the adjuvanted vaccine displayed significantly 
reduced weight loss and increased survival following infection with H5N1 
compared to mice that received the non-adjuvanted vaccine. Increased levels of 
antibodies were detected in mice that received either the adjuvanted H5N1 
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vaccine or the seasonal vaccine compared to mice that received the non-
adjuvanted H5N1 vaccine. In vitro, both the seasonal and adjuvanted H5N1 
vaccines more efficiently activated dendritic cells (DCs) when compared to the 
non-adjuvanted H5N1 vaccine, as seen by enhanced levels of cytokine 
production following treatment with the seasonal vaccine and an increase in co-
stimulatory molecule expression following treatment with adjuvanted H5N1 
vaccine. When treated with the adjuvanted H5N1 vaccine, DCs demonstrated 
increased antigen uptake and intracellular processing compared to cells treated 
with the non-adjuvanted vaccine. Pre-treatment with mannan or mannose 
diminished cytokine production by DCs in a dose dependent manner following 
seasonal, but not H5N1, vaccine treatment implicating C-type lectin receptor 
activation as the mechanism by which the seasonal vaccine elicits protection. 
These findings provide an explanation for attenuated DC function following H5N1 
vaccination, and while an alum adjuvant is able to rescue H5N1 vaccine 
immunogenicity it does so via a different mechanism than that utilized by 
seasonal influenza vaccines. Furthermore, these studies provide insight into the 
development of more immunogenic vaccines targeting HPAI.     
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CHAPTER ONE: INTRODUCTION 
Background 
Influenza viruses cause annual global epidemics that result in three to five 
million cases of severe illness and between 250,000 and 500,000 deaths 
worldwide with approximately 36,000 deaths occurring in the United States [1, 2]. 
Symptoms include fever, cough, muscle and joint pain, severe malaise, sore 
throat, and runny nose. Most affected people recover within a week, but as 
mentioned above, severe illness and death can occur [2]. Seasonal epidemics 
affect people of all ages, but high risk groups include children under the age of 
two, adults age 65 and older, and people with chronic diseases or weakened 
immune systems [2]. Vaccination is the most effective means of preventing 
influenza infection, and it is estimated that 70%-90% of vaccinated healthy adults 
are protected from the virus [2]. 
In addition to epidemics, influenza viruses can also cause occasional 
pandemics. The most severe pandemic in the 20th century was the 1918 
“Spanish Influenza” pandemic during which it is estimated that more than 50 
million people died worldwide [1]. The most recent pandemic was the 2009 novel 
H1N1 or “Swine Flu” pandemic. Circulation of the 2009 H1N1 virus resulted in a 
pandemic because it consisted of a unique combination of influenza virus genes 
that had never before been identified in animals or people, so pre-existing 
immunity to the virus did not exist [3]. It is estimated that, globally, between 
151,700 and 575,400 people died as a result of the 2009 H1N1 pandemic [4].      
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Highly pathogenic avian influenza (HPAI) viruses are a type of influenza 
virus with the potential to cause a pandemic [1]. As of April 26, 2013, the World 
Health Organization has reported 628 confirmed cases of HPAI subtype H5N1 
resulting in 374 deaths (59.5%) in 15 countries since 2003 [5]. Early symptoms of 
disease include fever, cough, and dyspnea, while severe cases result in fast 
progressing pneumonia, respiratory distress syndrome, damage to the central 
nervous system, and multi-organ failure with death usually occurring within 10 
days of symptom onset in fatal cases [6-8]. The potential for H5N1 to reach 
pandemic levels arises if, as with the 2009 H1N1 pandemic, the HA or NA 
segments from an HPAI virus were to be present in an influenza strain circulating 
in humans to which there is no pre-existing immunity. Vaccines targeting HPAI 
are being developed but they are not readily available, and early vaccines have 
been shown to be ineffective unless supplemented with an adjuvant [9-11]. The 
development of effective vaccines for HPAI reamins a priority. 
 
Influenza Viruses 
Influenza viruses are negative sense, segmented, single-stranded, RNA 
viruses that belong to the family Orthomyxoviridae, and they are organized into 
three genera commonly known as Influenza A, B, and C [7, 12-14]. Influenza A 
viruses naturally occur in aquatic birds, and are the only influenza viruses that 
infect birds. Influenza A viruses also infect a wider range of species including 
humans, swine, and several other species of mammals [12, 14]. Influenza B 
viruses infect humans and seals, and are less common and less genetically 
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diverse than Influenza A viruses [14-16]. Influenza C viruses infect humans and 
pigs, and while they may cause isolated epidemics, they are less common than 
Influenza A and B viruses and result in a more mild form of disease [2, 14, 17-
20]. Seasonal epidemics are caused by Influenza A and B viruses, while 
pandemics are the result of the introduction of a novel Influenza A subtype into 
the population for which there is limited or no pre-existing immunity [15, 21].  
The influenza viral genome is organized into eight segments that encode 
up to 13 proteins, including surface glycoproteins, polymerase proteins, structural 
proteins, and non-structural proteins [7, 14]. The genome is surrounded by a lipid 
envelope derived from the plasma membrane of the infected host cell. The 
hemagglutinin (HA) and neuraminidase (NA) glycoproteins radiate outward from 
the lipid envelope and are the major antigenic proteins of the virus, against 
which, neutralizing antibodies are produced [14] (Figure 1). The HA and NA 
proteins are also the most variable proteins due to the lack of proof-reading by 
the viral polymerase which results in mistakes in genome copying and frequent 
mutations. This concept is referred to as antigenic drift and is the reason a new 
influenza vaccine is needed every year [22]. Influenza viruses are also subject to 
antigenic shift.  Antigenic shift results when new HA and NA proteins enter the 
human population as a consequence of genetic reassortment between an 
influenza virus circulating in humans and an influenza virus circulating in another 
species such as pigs or birds [22]. Antigenic shift often results in a pandemic 
strain of influenza as the HA or NA segment of the new virus has most likely not 
circulated in humans before. [22].    
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Influenza A viruses are divided into subtypes based on the antigenic 
properties of the HA and NA proteins as determined by phylogeny [13, 14, 21]. 
As of 2012, 17 HA and 9 NA subtypes have been identified and characterized [7, 
13, 23]. The subtypes H3N2 and H1N1 circulate in humans as the seasonal 
viruses, along with Influenza B. Influenza B viruses are not divided into subtypes, 
but are further classified into strains [20]. HPAI viruses are limited to the H5 and 
H7 subtypes, but not all H5 and H7 viruses are highly pathogenic. Some are 
designated as low pathogenic avian influenza (LPAI) viruses [12]. There is a 
standard nomenclature system for influenza viruses that consists of the antigenic 
type (A, B, or C), the host of origin (duck, equine, swine), geographical origin, 
strain number, and year of isolation. The host of origin is omitted for human 
isolates. For Influenza A viruses, this nomenclature is followed by the antigenic 
description in parentheses [20, 24]. For example, A/Vietnam/1203/2004 (H5N1) 
is an Influenza A virus isolated from a human in Vietnam in 2004.    
 
Highly Pathogenic Avian Influenza 
All Influenza A viruses, including HPAI viruses, occur naturally in wild 
aquatic birds; however, they are occasionally transmitted to other hosts, such as 
domestic poultry and mammals, causing transient infections and occasional 
deaths [7, 25, 26]. On rare occasions, when influenza viruses are transmitted 
from aquatic birds to other species, continuous infections are established 
resulting in permanent influenza lineages in those hosts such as the seasonal 
influenza viruses that affect humans [25]. Therefore, HPAI viruses do not 
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normally infect humans, but rare cases do occur. Most human infections with 
HPAI are the result of close contact with infected poultry. Human-to-human 
transmission is rare, limited, and unsustainable [26]. Reports of human-to-human 
transmission include isolated household clusters of infection and a case where a 
child transmitted the infection to her mother [27, 28]. 
The first H5N1 virus outbreak in humans occurred in 1997 in Hong Kong.  
During this time, the virus was first identified in a 3-year-old boy who died in a 
Hong Kong hospital from Reye’s syndrome, acute influenza pneumonia, and 
respiratory distress syndrome. The outbreak resulted in a total of 18 confirmed 
cases resulting in 6 deaths [29-33]. Following the 1997 outbreak, avian influenza 
was not detected in humans again until 2003 [33]. The new cases of H5N1 were 
identified in a family of five from Hong Kong who had been visiting mainland 
China, and who had been in close contact with live chickens. Three of the family 
members became ill and two died from the disease [33]. By July 16, 2004, the 
HPAI epidemic had affected eight countries and resulted in at least 23 deaths 
[34]. Since 2003, human cases of H5N1 have persisted with 628 confirmed 
cases resulting in an approximate 60% fatality rate as of April 26, 2013 [5]. In 
2013, a novel HPAI H7N9 virus outbreak began to affect China [35, 36]. This is 
the first time an influenza A virus with an N9 subtype has been documented in 
humans [36]. The first cases were reported in February 2013, and as of May 30, 
2013, 132 cases have been confirmed resulting in 37 deaths (28%) with new 
cases being reported daily [37]. HPAI viruses therefore remain a current and 
future threat to public health. 
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Influenza Vaccines 
Vaccination is the most effective means for the prevention and control of 
infectious diseases, including influenza [38, 39]. Vaccination against influenza 
prevents 70%-90% of influenza specific illness in healthy adults, as well as, 
decreases severe illness and complications in the elderly by 60% and deaths by 
80% [2].  In the United States, there are two types of influenza vaccines 
approved for use: 1) the injectable inactivated trivalent influenza vaccine (TIV) 
approved for use in people aged 6 months and older, and 2) the intranasal live 
attenuated influenza vaccine (LAIV) approved for use in people aged 2 to 49. 
Neither the TIV nor the LAIV utilizes an adjuvant [40-43]. The TIV is the 
traditional influenza vaccine, and remains the most widely used [41]. Inactivated 
influenza vaccines were first shown to be effective during World War II, and since 
then, they have been repeatedly shown to be effective [44-48]. The TIV influenza 
vaccine has been recommended for use since 1960; however, its use possesses 
some limitations including lower immunogenicity in the very young and the 
elderly, and, since it is administered intramuscularly, it needs to be given by 
trained personnel [41, 43]. 
The LAIV vaccine was licensed for use in 2003 by the United States Food 
and Drug Administration (USFDA) [43]. It has some advantages over the TIV as 
it has been shown to have higher immunogenicity compared to the TIV and can 
be administered intranasally [40, 41]. Also, whereas the TIV only induces a 
systemic immune response, the LAIV induces both a systemic and mucosal 
immune response [41]. The LAIV contains live attenuated virus that is cold-
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adapted, which means it can only replicate and grow at temperatures less than 
25°C. This adaptation should prevent the virus from growing in the lungs and 
respiratory tract following vaccination; however, since the vaccine does contain 
live virus, there are safety concerns, especially in people with weakened immune 
systems [41, 42]. Both the TIV and the LAIV are trivalent vaccines using the 
same vaccine strains [40, 41]. Herein, focus will be placed on the TIV. 
Influenza vaccine production is a standardized process, and the complete 
manufacturing process takes about five to six months [49, 50]. The World Health 
Organization’s Global Influenza Surveillance Network, consisting of five influenza 
centers in London, Tokyo, Melbourne, Memphis, and Atlanta, continuously 
monitors circulating strains of influenza [49, 50]. Vaccine strains are chosen 
based on the circulating viruses and consist of three different influenza viruses, 
hence the trivalent nature of the vaccine. Two of the three viruses included in the 
annual vaccines are Influenza A viruses, an H3N2 and an H1N1, while the third 
virus is an Influenza B strain [49, 51].  
Following selection of the vaccine strains, the viruses are grown in 
fertilized chicken eggs along with A/Puerto Rico/8/1934 (H1N1) (PR8), a 
standard laboratory virus that grows quickly and efficiently in eggs. As the viruses 
grow and replicate, reassortment occurs in which the eight segments from each 
virus recombine forming hybrid viruses that contain a mixture of segments from 
each strain. The target viruses contain the HA and NA segments from the viruses 
chosen for the vaccine and all other segments from PR8. Antibodies against the 
HA and NA segments from PR8 can be included during the culture process to 
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help select for the target viruses (Figure 2). It takes approximately three weeks to 
prepare the hybrid viruses. Once the hybrid viruses have been generated, they 
are verified at one of the influenza surveillance centers to make sure they are 
safe, can grow in eggs, express the correct HA and NA proteins, and to ensure 
that they can produce a robust immune response. The vaccine strains are then 
distributed to vaccine manufacturers [49, 50].    
After receiving the vaccine strains from the influenza surveillance centers, 
the manufacturers must mass produce the viruses in order to have a large 
enough quantity to generate an adequate amount of vaccine. The viruses are 
again grown in fertilized chicken eggs, and it takes thousands of eggs to produce 
a sufficient amount of virus [50]. The viruses are inactivated, or “killed”, with 
formaldehyde, followed by purification in a linear sucrose density gradient 
solution using continuous flow centrifugation. The viruses are then chemically 
disrupted using Octylphenol Ethoxylate (Triton® X-100) producing a split virus. A 
split virus consists of pieces of the virus rather than an intact viral particle. The 
split virus is further purified so that it contains only the HA and NA proteins, thus 
designating it a subunit vaccine. The viral proteins are then suspended in sodium 
phosphate-buffered isotonic sodium chloride solution creating the final vaccine 
preparation [52]. Each batch, or lot, of the vaccine is tested for sterility and 
amount of protein, or antigen. The vaccine then undergoes clinical trials for 
safety evaluation, and to show that it performs as expected. Clinical trials are not 
required in all countries as previous studies on annual influenza vaccines were 
performed and the assumption is that the new vaccines will behave similarly. The 
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vaccine must then be approved by regulatory agencies before it can be 
introduced into the national immunization program [50].      
An inactivated subunit vaccine targeting the HPAI strain 
A/Vietnam/1203/2004 (H5N1) has been developed using the methods described 
above, and 20 million doses of this vaccine have been stockpiled in the United 
States in case of a pandemic [53]. Despite the ability of seasonal influenza 
vaccines and the 2009 H1N1 pandemic vaccine to stimulate the production of 
protective antibody titers, the H5N1 vaccine was shown to have low 
immunogenicity [2, 11, 44-48]. Vaccine efficacy in humans is determined by the 
production of antibodies against HA with titers of greater than 1:40 deemed 
protective. When evaluated in clinical trials, 70% of Fluzone® 2009/2010 TIV 
vaccine recipients developed protective antibody titers, and 95%-100% of 
Fluzone® 2009 H1N1 pandemic TIV vaccine recipients developed protective 
antibody titers [47, 48]. When the H5N1 subunit vaccine was evaluated in clinical 
trials, only 22% of recipients developed protective antibody titers (Figure 3) [11].  
 
Alum Adjuvants     
Adjuvants are substances that can be added to vaccines in order to 
augment the immune response. The term adjuvant comes from the Latin word 
“adjuvans” which means “to help” [54, 55]. The use of adjuvants was first 
exploited by William Coley, who used bacterial components to treat cancer 
patients, and by Ramon and Glenny who used tapioca and aluminum hydroxide 
along with diphtheria and tetanus toxins to enhance responses in horses and 
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guinea pigs [54]. The adjuvant alum, which is based on aluminum salts, is the 
most widely used adjuvant worldwide, and until recently was the only adjuvant 
approved for use in the United States [54-57]. The adjuvant AS04, which is a 
combination of monophosphoryl lipid A (MPL), a derivative of the bacterial cell 
wall component lipopolysaccharide (LPS), and alum, was approved for use in 
2009 for the Cervarix vaccine targeting human papilloma virus (HPV) [56, 58]. 
Other vaccines licensed for use in the United States that contain alum include 
those for diphtheria, tetanus, and pertussis (DTaP), hepatitis A and B, 
pneumonia, anthrax, and rabies. Approved influenza vaccines do not contain an 
adjuvant [59].  
It is not fully understood how adjuvants function, and they have been 
shown to act in many different ways to enhance immunity to an antigen. The term 
antigen refers to a foreign substance that induces an immune response [60]. 
Many adjuvants seem to stimulate antigen presenting cells (APCs) such as 
dendritic cells (DCs) enhancing maturation, migration, antigen presentation, and 
the expression of co-stimulatory molecules which leads to improved responses of 
T and B cells [54]. Alum has been shown to work in several different ways 
leading to confusion and controversy surrounding its mechanism of action [54-56, 
61]. In vaccines containing alum, antigens are adsorbed onto the aluminum salts 
and the mixture is injected intramuscularly creating a nodule at the site of 
injection. The original theory behind the mechanism of action of alum, which is 
still widely believed, is that alum acts as an “antigen depot” by slowly releasing 
antigen to the immune system and prolonging exposure [54-57]. One study 
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showed, however, that removal of the alum nodule one week following 
vaccination had no effect on the antibody response generated against the 
pathogen [62], while another study demonstrated that adsorption of the antigen 
to alum was not required for the ability of alum to enhance the immune response 
[63]. If the antigen is not adsorbed to alum, then prolonged exposure at the depot 
is not taking place.  
Another mechanism of action demonstrated for alum is the activation of 
the NLRP3 (also known as NALP3) inflammasome immune complex [64]. The 
NLRP3 inflammasome complex is a molecular platform consisting of the proteins 
NLRP3, ASC, and pro-caspase-1. Activation of the inflammasome in turn leads 
to activation of caspase-1. Activated caspase-1 then proteolytically cleaves pro-
IL1β and pro-IL18 resulting in the secretion of their biologically active forms, the 
pro-inflammatory cytokines IL1β and IL-18, which induce an anti-microbial 
response [65]. NLRP3 inflammasome activation requires two signals, and alum 
has been shown to provide the second signal which directly activates NLRP3. 
The first signal is provided by endogenous or microbial antigens that activate NF-
κB and induce NLRP3 expression [64, 65]. Antigens that provide the first signal 
include lipopolysaccharide (LPS), muramyl dipeptide (MDP), bacterial RNA, the 
dsRNA analog polyI:C, and microbial lipopeptide [65]. While alum has been 
shown to activate the NLRP3 inflammasome pathway, other studies have 
demonstrated that alum can enhance the immune response in the absence of 
inflammasome activation [66].    
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A third means by which alum has been shown to function as an adjuvant 
is through increasing antigen uptake by DCs [67, 68]. To this end, alum was 
shown to interact directly with lipids on the cell surface of DCs, specifically 
sphingomyelin and cholesterol, promoting lipid sorting in the plasma membrane. 
The lipid sorting activated an endocytic response which led to increased antigen 
uptake. In addition to antigen uptake, the lipid sorting also triggered Syk and 
phosphoinositide 3-kinase (PI3K) signaling pathways inducing an immune 
response [67, 68]. Interestingly, the study demonstrated that while alum 
facilitates increased antigen uptake, the adjuvant itself does not enter the cell, 
rather it remains at the plasma membrane [67, 68].  
Regardless of the mechanism, alum adjuvants are known to induce robust 
antibody responses, and have been shown to promote a T-helper 2 (TH2) type 
immune response rather than a T-helper 1 (TH1) type immune response, referring 
to the subset of CD4+ T cells being activated [56, 57, 64]. TH2 responses are 
associated with IL-4 production and the generation of IgG1 and IgE antibodies, 
whereas TH1 responses are associated with the production of high levels of IFNγ, 
the secretion of IL-12, and the generation of IgG2 antibodies [56, 57, 64]. TH1 
responses are known to operate through Toll-like receptors (TLRs,) and it has 
been demonstrated that alum does not directly activate TLRs [56].    
 
The Immune Response to Vaccination 
The immune response to vaccination is initiated by the recognition of 
foreign antigen by innate immune cells such as dendritic cells (DCs), 
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macrophages, and neutrophils. DCs and macrophages function as antigen 
presenting cells (APCs) [61, 69], and DCs in particular, have been shown to be 
important for the recognition of vaccine antigens, which they detect via germline-
encoded pathogen receptors known as Pattern Recognition Receptors (PRRs) 
[70]. PRRs recognize conserved microbial structures called Pathogen Associated 
Molecular Patterns (PAMPs) found on a variety of microbes, such as bacteria, 
viruses, yeast, fungi, protozoa, and parasites [61, 69, 71]. PAMPS include, but 
are not limited to, peptidoglycans, lipopolysaccharides, and viral RNA and DNA 
[61, 69]. Several classes of PRRs have been identified and include: Toll-like 
receptors (TLRs), nucleotide-oligomerization domain (NOD)-like receptors 
(NLRs), and C-type lectin receptors (CLRs) which recognize a variety of 
pathogens; as well as retinoic acid-inducible gene-1 (RIG-1)-like receptors 
(RLRs) which recognize viral nucleic acids [39, 72-75].  
TLRs are the most widely studied PRRs [69]. Eleven TLRs have been 
identified in humans and 13 TLRs have been identified in mice, with TLRs 1-9 
being conserved between humans and mice [69, 71]. TLRs 1, 2, 4, 5, and 6 are 
expressed on the cell surface and recognize PAMPs from bacteria, fungi, and 
protozoa. TLRs 3, 7, 8, and 9 are located in cellular endosomal compartments 
and recognize bacterial and viral nucleic acids [69]. Influenza viruses are 
recognized by TLR3, which senses dsRNA, and TLR7/8 which senses ssRNA 
[76]. TLRs are type 1 transmembrane glycoproteins that consist of extracellular 
leucine rich repeats (LRRs) important for pathogen recognition, and a 
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cytoplasmic Toll/interleukin-1 receptor (TIR) domain required for signaling [69, 
77].      
NLRs recognize cytosolic PAMPs as well as host derived molecules 
associated with danger or stress referred to as Danger Associated Molecular 
Patterns (DAMPs) [69, 78]. DAMPs include molecular crystals, reactive oxygen 
species, potassium efflux, and ATP [78]. Twenty three NLRs have been identified 
in humans and approximately 34 have been identified in mice. NOD1 and NOD2 
are among the most well studied members of the NLR family [79]. Additionally, 
NLRP1, NLRP3, and NLRC4 are NLR family members that form inflammasomes 
[74]. Structurally, NLRs consist of 3 domains: a C-terminal leucine rich repeat 
(LRR) domain which is important for the recognition of PAMPs and DAMPs; an 
N-terminal Caspase Recruitment Domain (CARD) important for signaling; and a 
centrally located nucleotide-binding oligomerization domain (NBD or NACHT) 
also required for signaling [69, 79]. 
CLRs are a large superfamily of proteins that contain one or more C-type 
lectin-like domain (CTLD), and they are divided into 17 groups based on 
functional and structural characteristics [72, 74]. The term C-type lectin comes 
from the original observation that their activities were calcium dependent; 
however, some CLRs have since been identified to function in a calcium 
independent manner [72]. Structurally, CLRs contain at least one carbohydrate 
recognition domain (CRD); however, not all CLRs bind carbohydrates [72, 73]. 
CLRs exist as both transmembrane and cytosolic receptors. Those that function 
as PRRs are the transmembrane receptors which recognize carbohydrates, 
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specifically mannose, fucose, and glucan structures. With carbohydrates as their 
ligands, CLRs recognize most types of human pathogens [72, 73]. There are two 
main ways in which CLRs induce signaling cascades. The first is through adaptor 
molecules that contain immunoreceptor tyrosine-based activation motifs (ITAMs), 
such as FcRγ chains. The second is through the activation of protein kinases or 
phosphatases that interact, either directly or indirectly, with the cytoplasmic tails 
of the receptors [73, 74]. CLR family members include DC-SIGN, Dectin-1, 
Dectin-2, Mincle, and CLEC5A [73, 74].  
In general, the activation of PRRs is followed by signaling cascades which 
lead to the activation of transcription factors, such as NF-κB, followed by the 
regulation of cytokine gene expression and the secretion of pro-inflammatory 
cytokines such as IL-6, IL-12, IL-1β, and TNF-α [39, 72-75, 77, 79, 80]. Following 
recognition, antigens are internalized by DCs and degraded into small peptides. 
The peptides are processed and presented to T cells via major histocompatibility 
complex (MHC) class I or class II molecules which interact with the T cell 
receptor (TCR) on naïve T cells [61, 70]. Activated DCs also up-regulate the 
expression of co-stimulatory cell-surface molecules such as CD80/CD86 and 
CD40, which bind their cognate receptors CD28 and CD40L, respectively, on the 
surface of naïve T cells [61, 70]. Antigen-MHC interaction with the TCR, together 
with co-stimulatory molecule interaction with cognate receptors, provides a dual 
signal leading to the activation of naïve T cells.  
Activated T cells produce cytokines such as IL2, IL-4, IL-7, IL-15, and IFN-
γ which enhance T cell proliferation (clonal expansion) and survival, have 
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important anti-microbial functions, and influence B cell differentiation and 
antibody production [60, 61, 70]. T cells are categorized based on their function, 
with the most well characterized populations consisting of helper T cells (CD4+) 
and cytotoxic T cells (CD8+) [60]. Cytotoxic T cells eliminate infected cells, while 
helper T cells assist macrophages in the elimination of pathogens and also 
stimulate B cells responses and antibody production [60, 70].  
B cells are the only type of cells that produce antibodies. Antibodies 
recognize microbial antigens, bind to the microbe, block the ability of the microbe 
to infect host cells, and target the microbe for destruction by various mechanisms 
[60]. B cells secrete five different types of antibodies in response to different 
types of pathogens, and each class of antibody has a distinct structure, function, 
and location within the body. The different classes of antibodies are referred to 
as isotypes and consist of IgG, IgE, IgM, IgA, and IgD, with the prefix “Ig” 
referring to immunoglobulin, another term for antibody indicative of protein 
structure [60, 81].  
IgG is the main class of antibody found in the serum and is important for 
the response to viruses and bacteria, and it is the only antibody isotype that can 
cross the placental barrier providing passive immunity to the fetus. There are four 
subclasses of IgG in humans (IgG1, IgG2, IgG3, and IgG4) [60, 81]. Influenza 
vaccines, as with most vaccines, provide protection by inducing antibody 
responses, specifically IgG responses [39, 82].       
 
17 
 
Purpose of Study 
Highly pathogenic avian influenza viruses are an emerging threat to public 
health with the potential to cause a pandemic. While a split virion subunit vaccine 
has been developed according to the process used for seasonal vaccines, it 
demonstrated low immunogenicity in clinical trials. The immunological 
mechanisms behind vaccination are incompletely understood. This dissertation 
includes the results from two original studies that examined differences in the 
immune response to an inactivated subunit seasonal vaccine and an inactivated 
subunit vaccine for H5N1 with and without the addition of an alum adjuvant. A 
better understanding of the mechanism by which vaccines confer protection 
could lead to the development of more effective vaccines. 
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Figure Legends 
Figure 1. Cartoon representation of an influenza virus. The influenza viral 
genome is comprised of eight segments of single-stranded RNA surrounded by a 
lipid envelope. The hemagglutinin (HA) and neuraminidase (NA) glycoproteins 
radiate outward from the lipid envelope.  
 
Figure 2. Influenza subunit vaccine manufacturing process. A. The influenza 
virus that the vaccine will target (in this example, A/Vietnam/1203/2004 (H5N1) 
(VN1203)) is grown in fertilized chicken eggs along with the influenza virus 
A/Puerto Rico/8/1934 (H1N1) (PR8). While replicating in the eggs, genome 
segments from the two viruses will reassort forming hybrid viruses that contain 
segments from both viruses. The target virus for the vaccine will contain the HA 
and NA segments from VN1203 and all other segments from PR8. Antibodies 
against the HA and NA segments from PR8 can be included in the culture 
process to facilitate selection of the target virus. B. Once the target virus has 
been generated, it is again grown in fertilized chicken eggs. The virus is then 
harvested from the eggs and inactivated or “killed” with formaldehyde. Following 
purification in a linear sucrose gradient, the virus is chemically disrupted 
producing a split virus. The virus is then further purified so that it contains only 
the HA and NA proteins, which are then suspended in sodium phosphate-
buffered isotonic sodium chloride solution creating the final vaccine preparation. 
 
26 
 
Figure 3. Antibody titers following influenza vaccination in human clinical 
trials. When tested in human clinical trials, 70% of Fluzone® 2009/2010 TIV 
vaccine recipients and 95%-100% of Fluzone® 2009 H1N1 pandemic vaccine 
recipients developed protective antibody titers greater than 1:40. Only 22% of 
H5N1 inactivated subunit vaccine recipients developed protective antibody titers 
greater than 1:40. This graph is adapted from Plennevaux, E., et al., Lancet, 
2010 [47], Xie, H., et al., PLosONE, 2011 [48], and Treanor, J.J. et al., New 
England Journal of Medicine, 2006 [11].     
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vaccination results from impaired C-type lectin receptor signaling 
 
Sarah E. Vaughan1,2, Heather W. Stout-Delgado1, Zemmie E. Pollock1, Jennifer 
R. Plourde1,2, John A. Pyles1, Bridget S. Wilson2, and Kevin S. Harrod1,# 
 
1Infectious Diseases Program, Lovelace Respiratory Research Institute, 
Albuquerque, NM, 87108 
 
2Biomedical Sciences Graduate Program, University of New Mexico, 
Albuquerque, NM, 87131 
 
# Email:kharrod@lrri.org 
 
Conceived and designed experiments: SEV, HWS, BSW, KSH.  Performed the 
experiments: SEV, HWS, ZEP, JRP, JAP.  Analyzed the data: SEV, HWS, KSH.  
Wrote the paper: SEV, KSH. 
  
31 
 
Abstract 
Highly pathogenic avian influenza (HPAI) H5N1 has an approximate 60% 
fatality rate in humans. In the United States, a vaccine for H5N1 has been 
manufactured and stockpiled using FDA approved methods for seasonal 
influenza vaccines. In clinical trials, the H5N1 vaccine was shown to be less 
immunogenic compared to seasonal vaccines. Herein, we utilized a BALB/c 
mouse model to elucidate the underlying immune mechanisms by which 
immunization with the HPAI vaccine results in attenuated immunogenicity. Mice 
that received the seasonal vaccine produced a robust neutralizing antibody 
response whereas no neutralizing antibodies were detected following HPAI 
vaccination. Bone marrow derived dendritic cells (BMDCs) cultured with the 
seasonal vaccine produced significantly higher levels of the pro-inflammatory 
cytokines IL-6, IL-12, and TNF-α compared to those treated with the H5N1 
vaccine, indicating increased antigen presenting cell (APC) activation. Neither 
vaccine stimulated Toll-like receptors nor NOD-like receptors; therefore, as C-
type lectin receptors have been implicated as a class of pattern recognition 
receptors involved in innate immunity and immunization their involvement was 
examined. Pre-treatment with mannan or mannose diminished cytokine induction 
by DCs in a dose dependent manner following seasonal but not HPAI vaccine 
treatment, suggesting a role for C-type lectin receptors in DC activation by the 
seasonal influenza vaccine. BMDCs pre-treated with the H5N1 vaccine displayed 
decreased cytokine production following treatment with either the seasonal 
vaccine or mannan suggesting that the HPAI vaccine is binding to the receptors 
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but not inducing a signaling cascade. These findings provide a novel role for C-
type lectin receptors in influenza vaccination, and a potential mechanism for 
attenuated APC function following H5N1 vaccination and may explain the 
decrease in immunogenicity of the currently approved HPAI vaccine. 
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Introduction 
Highly pathogenic avian influenza (HPAI) H5N1 is an emerging infectious 
virus associated with occasional illness and death in humans. Recent outbreaks 
have occurred in Cambodia, Bangladesh, China, and Egypt [1, 2]. So far, in 2013 
documented cases have resulted in a 78% mortality rate, with the overall 
mortality rate being slightly lower at 60% [1]. Symptoms in affected people 
include fast progressing pneumonia, respiratory distress syndrome, damage to 
the central nervous system, and multi-organ failure, and death usually occurs 
within 10 days of symptom onset in fatal cases [3, 4]. The high lethality rate and 
occasional infection in humans make an H5N1 pandemic feasible; therefore, an 
effective vaccine targeting H5N1 is a high priority, especially in affected countries 
[5-7].       
As part of the pandemic preparedness plan, the United States has 
stockpiled 20 million doses of an inactivated subunit vaccine targeting H5N1 [8]. 
The H5N1 vaccine is manufactured employing the same techniques used to 
generate seasonal influenza subunit vaccines [9]. In clinical trials, seasonal 
influenza subunit vaccines have demonstrated the ability to produce protective 
antibody titers, which are considered to be greater than 1:40, in the majority of 
recipients. One study demonstrated that 70% of recipients developed protective 
titers to the 2009/2010 seasonal vaccine, and another showed 95%-100% of 
recipients developed protective titers to the 2009 novel H1N1 influenza vaccine 
[10, 11]. When the H5N1 vaccine was tested in clinical trials, however, only 22% 
of recipients developed protective antibody titers [12].     
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The use of vaccines is one of the most effective means for preventing 
infectious diseases [13]. Recognition of foreign antigen by innate immune cells, 
such as dendritic cells (DCs), initiates the immune response to vaccination. DCs 
function as antigen presenting cells (APCs) by responding to, processing, and 
presenting antigen to T cells [14]. DCs detect antigen via germline-encoded 
pathogen receptors known as pattern recognition receptors (PRRs). PRRs 
recognize conserved molecular structures found on groups of pathogens referred 
to as pathogen-associated molecular patterns (PAMPs) [15, 16]. PRRs include 
Toll-like receptors (TLRs), nucleotide-oligomerization domain (NOD)-like 
receptors (NLRs), and C-type lectin receptors (CLRs) which recognize a variety 
of pathogens, as well as retinoic acid-inducible gene-1 (RIG-1)-like receptors 
(RLRs) which recognize viral nucleic acids  [13, 15-18]. The activation of PRRs is 
followed by signaling cascades which lead to the activation of transcription 
factors and the subsequent regulation of cytokine gene expression, and this 
process helps shape effective adaptive immune responses [13, 15-18].  
The specific mechanisms by which vaccines induce protective immunity 
remain to be elucidated [13]. Herein, we utilized a vaccination model in BALB/c 
mice to study the mechanism by which the seasonal influenza vaccine elicits a 
more robust antibody response than the H5N1 vaccine. We show that treatment 
with the seasonal vaccine results in increased total and functional antibody 
production in BALB/c mice. In vitro, BMDCs treated with the seasonal vaccine 
produced higher levels of pro-inflammatory cytokines compared to cells treated 
with the H5N1 vaccine; however, APC activation was not via TLRs or NLRs. The 
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seasonal vaccine stimulated CLRs to induce pro-inflammatory cytokine 
production, whereas the H5N1 vaccine bound CLRs but did not initiate APC 
activation. These findings describe a novel role for C-type lectin receptors in 
influenza vaccination, as well as, a potential mechanism for attenuated APC 
function following H5N1 vaccination providing insight into the development of 
more immunogenic vaccines targeting HPAI. 
 
Materials and Methods 
Mice 
Male BALB/c mice, aged six to eight weeks, were purchased from the 
National Cancer Institute at Frederick (NCI-Frederick, Bethesda, MD), and were 
held for 21 days for quarantine and acclimation.  Mice were housed four per cage 
in microisolator cages under identical husbandry conditions and fed certified 
commercial feed. All animal studies were approved by the Lovelace Respiratory 
Research Institute Internal Animal Care and Use Committee.   
 
Vaccines 
The following reagents were obtained through the National Institutes of 
Health (NIH) Biodefense and Emerging Infections (BEI) Research Resources 
Repository, NIAID, NIH: Monovalent Influenza Subvirion Vaccine, 
rg/A/Vietnam/1203/2004, NR-4143 and Fluzone® Influenza Virus Vaccine, 2009-
2010 Formula, NR-19879 at concentrations of 30ug/ml hemagglutinin protein. 
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Vaccines were diluted to 0.6ug/ml HA protein within 0.05ml physiological saline 
immediately prior to vaccination. 
 
Viruses 
Influenza virus A/Brisbane/59/2007 subtype H1N1 was obtained from the 
Centers for Disease Control and Prevention (Atlanta, GA) as low-passage stock.  
The virus was passaged once in 10-day old embryonated chicken eggs to 
generate the master stock and then twice in eggs and once in Madin-Darby 
Canine Kidney (MDCK) cells to generate the virus for all subsequent uses.  
Aliquots of 0.5ml to 1ml were stored at -80°C. After storage, the virus was 
determined to have a concentration of 4.85 x 106 tissue culture infectious dose 
50 (TCID50). 
Influenza virus A/Vietnam/1203/2004 (VN1203) subtype H5N1 was 
obtained from the Centers for Disease Control and Prevention (Atlanta, GA) as 
low-passage stock. The virus was passaged once in 10-day old embryonated 
chicken eggs to generate the master stock and then twice in eggs to generate 
the virus for all subsequent uses. Aliquots of 0.5ml to 1ml were stored at -80°C.  
After storage, the virus was determined to have a concentration of 1.4 x 108 
plaque forming units (pfu/ml), 5.8 x 108 50% tissue culture dose (TCID50/ml), and 
1 x 108 50% egg infectious dose (EID50/ml). Influenza A/Vietnam/1203/2004 is a 
Risk Group 3 pathogen and all experiments involving this virus were carried out 
in a Biosafety Level 3 (BSL 3) containment facility at the Lovelace Respiratory 
Research Institute and approved by the Institutional Biosafety Committee. 
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Vaccination and Serology 
Mice (n = 6 per group, except seasonal IM where n = 18 as this group was 
performed separately) were given either a subcutaneous (SC) or intramuscular 
(IM) injection of 0.6ug seasonal influenza or HPAI vaccine in the gastrocnemius 
muscle. Control animals received injections of 0.05ml physiological saline either 
IM or SC. Blood for serum was collected in serum separator collection tubes 3 
weeks following vaccination by cardiac puncture, and incubated at room 
temperature for 30 minutes before centrifugation at 2500rpm for 10 min. Serum 
was collected and kept at -20°C until analyzed. The neutralization assay was 
modified from previously described procedures [19]. Briefly, serum samples were 
treated with receptor-destroying enzyme (RDE (II)), (Enka-Seiken, Tokyo, 
Japan), at a ratio of 1:1 followed by heat inactivation at 56°C for 45 minutes. The 
serum samples were incubated with 2 x 103 TCID50 A/Brisbane/59/2007 or 
A/Vietnam/1203/2004 at 37°C for one hour.  After incubation, MDCK cells plated 
in 96 well plates were inoculated in triplicate with the samples using a 2-fold 
dilution and incubated at 37°C for three days. The plates were then scored for 
cytopathic effect (CPE), and neutralizing antibody titers were determined as the 
highest serum dilution at which no CPE occurred. 
Total vaccine specific IgG was determined by ELISA using modified 
previously described techniques [20]. Briefly, 96-well plates were coated with 
1ug/ml seasonal or H5N1 vaccine in coating buffer (eBioscience, San Diego, CA. 
Catalog # 00-0044-59) and incubated overnight at 4°C. Following incubation, 
plates were washed with 1x PBS containing 0.05% Tween® 20 (Sigma-Aldrich, 
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St. Louis, MO). Plates were blocked with 1x assay diluent (eBioscience. Catalog 
#00-4202) for 1 hour at room temperature before incubation with serum samples 
from vaccinated mice, diluted 1:10,000 in assay diluent, for 2 hours at room 
temperature. Following additional washes, total vaccine specific IgG was 
determined by incubation with horse anti-mouse IgG (H & L) conjugated to HRP 
(Cell Signaling Technology, Danvers, MA) at a 1:250 dilution in assay diluent for 
1 hour at room temperature. Following a wash step, TMB substrate solution 
(eBioscience) was added to develop color, and 2N H2SO4 was added to stop the 
reaction. Plates were read at 450nm absorbance, and optical density (OD) 
values are reported.   
 
Primary Bone Marrow Cell Isolation and Culture 
Bone marrow cells were collected and cultured using previously described 
methods [21]. Briefly, bone marrow cells were isolated from the femurs and tibiae 
of BALB/c mice and cultured in complete RPMI media (Invitrogen, Carlsbad, CA) 
containing 10% FBS (Invitrogen), 1x penicillin/streptomycin (Invitrogen), and 
25ng/ml GM-CSF (Cell Signal Technology, Danvers, MA) for 5-7 days at 37°C 
with 5% CO2. 
 
Cytokine Analysis 
BMDCs in complete RPMI media were treated with either seasonal 
influenza vaccine or H5N1 vaccine at a concentration of 0.6ug/ml (HA protein), 
100ng LPS-EB (InvivoGen, San Diego, CA), or media alone for 24 hours. Cell 
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culture supernatants were analyzed for IL-6, IL-12, and TNF-α production using 
ELISA kits purchased from eBioscience according to the manufacturer’s 
instructions. 
 
TLR/NLR Expression Assay 
THP1-XBlue cells were purchased from InvivoGen and cultured according 
to the manufacturer’s recommendations. The cells express TLRs 1-9 as well as 
NOD1/2 and are stably transfected with an NF-κB and AP-1 inducible secreted 
embryonic alkaline phosphatase (SEAP) reporter gene. Upon TLR/NLR 
stimulation, THP1-XBlue cells activate the transcription factors NF-κB and AP-1, 
and SEAP is secreted. SEAP can be detected by QUANTI-Blue (InvivoGen), 
which turns blue/purple in the presence of SEAP. Heat killed Listeria 
monocytogenes (HKLM) (InvivoGen) was used as a positive control for TLR2 and 
LPS-EB (InvivoGen) was used as a positive control for TLR4. The TLR assay 
was conducted according to the manufacturer’s instructions. Briefly, cells were 
plated at 200,000 cells per well in a 96 well plate. Cells were treated with 0.6ug 
seasonal influenza vaccine, 0.6ug H5N1 vaccine, 10ul of 1ug/ml LPS, or 10ul of 
reconstituted HKLM (109 cells/mL) for 24 hours. Following the overnight 
incubation, cell supernatants were incubated with QUANTI-Blue for 2 hours and 
SEAP levels were determined using a spectrophotometer at 620-655 nm. 
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C-Type Lectin Receptor Binding Assays  
BMDCs were pre-treated with increasing concentrations of either mannan 
(0ug/ml, 12.5ug/ml, 25ug/ml, 50ug/ml), mannose (0mg/ml, 0.5mg/ml, 5mg/ml, 
10mg/ml, 20mg/ml), or HPAI vaccine (0ug/ml, 0.5ug/ml, 1ug/ml, 1.5ug/ml, 
2ug/ml) for 30 min at 4°C. Cells pre-treated with mannan or mannose were 
treated with either seasonal influenza vaccine or HPAI vaccine at 0.6ug/ml 
overnight. Cells pre-treated with HPAI vaccine were treated with seasonal 
vaccine at 0.6ug/ml or mannose at 50ug/ml overnight. Cytokine expression was 
determined by ELISA as described previously.  
         
Results 
Antibody Titers in Vaccinated Mice 
Human clinical trials have demonstrated that robust protective antibody 
responses are produced in response to seasonal influenza vaccination, but 
vaccination with the H5N1 vaccine leads to a much weaker antibody response 
[11, 12]. To examine differences in antibody production following vaccination, six 
to eight week old BALB/c mice were given either a subcutaneous (SC) or 
intramuscular (IM) injection of 0.6ug seasonal influenza or HPAI vaccine. 
Functional antibody titers were assessed by neutralization assay (Figure 1a) and 
total vaccine specific IgG was determined by ELISA (Figure 1b). Mice that 
received the seasonal vaccine by either route of vaccination had significantly 
increased levels of neutralizing antibodies compared to mice that received the 
HPAI vaccine, in which the amount of neutralizing antibodies was below the level 
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of detection. Eighty three percent of mice that received the seasonal vaccine SC, 
and 86% of mice that received the seasonal vaccine IM, had neutralizing 
antibody titers above the level considered protective (>1:40). When comparing 
total vaccine specific IgG, antibody titers in mice that received the seasonal 
vaccine mirrored the levels of neutralizing antibodies, and were significantly 
higher than in mice that received the HPAI vaccine. While neutralizing antibodies 
were not detected in mice that received an IM injection of the HPAI vaccine, low 
levels of total vaccine specific IgG were observed. Levels of total vaccine specific 
IgG in mice vaccinated IM with the HPAI vaccine were significantly higher when 
compared to mice that received a SC injection of the HPAI vaccine.   
 
APC Activation Following Vaccine Treatment 
It is well established that an effective adaptive immune response follows 
an efficient innate immune response, and the innate immune response to 
vaccination is initiated by recognition of foreign antigen by APCs, such as DCs. 
Following interaction with antigen, DCs become activated and produce pro-
inflammatory cytokines such as IL-6, IL-12, and TNF-α. Pro-inflammatory 
cytokine secretion is crucial for the activation and differentiation of T cells and the 
progression of the immune response [14, 22]. Differences in DC activation were 
evaluated in vitro by assessing pro-inflammatory cytokine production following 
vaccine treatment. Bone marrow derived dendritic cells (BMDCs) from BALB/c 
mice were treated with either the seasonal or HPAI vaccine for 24 hours, and 
cytokine production was analyzed by ELISA. BMDCs treated with the seasonal 
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vaccine produced significantly higher levels of IL-6, IL-12, and TNFα compared to 
BMDCs treated with the HPAI vaccine, which did not induce cytokine production 
(Figure 2a-c). LPS was used as a positive control and resulted in the production 
of similar, or greater, levels of IL-6, IL12, and TNFα when compared to the 
seasonal vaccine.   
DCs detect antigen via germline-encoded pathogen receptors known as 
Pattern Recognition Receptors (PRRs), specifically Toll-like receptors (TLRs) 
[22, 23]. TLRs are a class of PRRs that reside on the cell surface or in the 
endosomal compartments of innate immune cells. One of the most important 
consequences of TLR signaling is the transcriptional regulation of inflammatory 
genes, such as IL-6, IL-12, and TNF-α [24]. Influenza viruses activate DCs by 
signaling through TLRs, specifically the endosomal TLR3 and TLR7/8 [25-27]. To 
determine whether the influenza vaccine also signals through TLRs, a THP-1 
reporter cell line expressing TLRs1-9 and NOD1/2 was utilized. THP-1 reporter 
cells were treated with either the seasonal or HPAI vaccine. Heat-killed Listeria 
monocytogenes (HKLM) and LPS were used as positive controls for TLR-2 and 
TLR-4 respectively. Neither vaccine treatment stimulated TLRs nor NOD1/2, 
showing levels of SEAP expression similar to that of cells treated with media 
alone (Figure 3). These data demonstrate that unlike influenza viruses, 
inactivated subunit vaccines targeting influenza do not signal through TLRs or 
NLRs. 
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C-Type Lectin Receptor Signaling Following Vaccine Treatment 
C-type lectin receptors (CLRs) have been implicated as a class of PRRs 
important for antigen recognition, internalization, and presentation to T cells [18, 
28-30]. The signaling cascades following pathogen binding to CLRs result in the 
production of pro-inflammatory cytokines [15, 18, 29]. To assess whether 
influenza vaccines are binding to CLRs, BMDCs were pre-treated with increasing 
concentrations of mannan, a CLR agonist, followed by treatment with either the 
seasonal or HPAI vaccine, and cytokine expression was assessed by ELISA. As 
expected, cells treated with the seasonal vaccine in the absence of mannan 
induced cytokine secretion, whereas cells treated with the HPAI vaccine in the 
absence of mannan did not produce cytokines. In cells treated with the seasonal 
vaccine, as the concentration of mannan increased, the production of the 
cytokines IL-6, IL-12, and TNFα decreased in a dose dependent manner (Figure 
4a-c). This data suggests that mannan and the seasonal vaccine are binding to, 
and signaling through, the same receptors. Interestingly, in BMDCs treated with 
the HPAI vaccine, as the concentration of mannan increased, the expression of 
the cytokines IL-6, IL-12, and TNFα also increased but remained lower than 
cytokine levels produced by cells treated with mannan alone, suggesting that the 
HPAI vaccine is binding CLRs but not inducing a signaling cascade.   
In order to more clearly demonstrate that the seasonal influenza vaccine is 
binding C-type lectin receptors, since mannan alone induces cytokine 
expression, mannose was used to block CLRs. CLRs recognize high-mannose 
structures that are able to induce receptor aggregation and consequent signaling. 
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The mannose monomer binds CLRs, but due to differences in valency, does not 
trigger receptor aggregation [15, 18, 31]. Following pre-treatment with mannose, 
BMDCs were treated with either the seasonal or HPAI vaccine. As with the 
mannan pre-treatment, in cells treated with the seasonal vaccine, as the 
concentration of mannose increased, the expression of the cytokines IL-6, IL-12, 
and TNF-α decreased in a dose dependent manner (Figure 5a-c). Again, this 
suggests that the seasonal vaccine is activating CLRs. As expected, treatment 
with the HPAI vaccine did not result in cytokine production, as this was previously 
demonstrated in Figure 2. 
   To further assess the possibility that the HPAI vaccine binds CLRs without 
inducing a signaling cascade, BMDCs were pre-treated with increasing 
concentrations of HPAI vaccine following treatment with either seasonal vaccine 
or mannan, and cytokine expression was assessed by ELISA. In both BMDCs 
treated with the seasonal vaccine or mannan, as the amount of HPAI vaccine 
increased, the expression of the cytokines IL-6, IL-12, and TNFα decreased in a 
dose dependent manner (Figure 6a-c). This data further implicates CLRs as the 
receptors engaged by the influenza vaccines and demonstrates that the HPAI 
vaccine is binding to the receptors but not initiating a signaling cascade.   
 
Discussion 
Despite utilizing similar techniques for the production of seasonal 
influenza subunit vaccines, the H5N1 subunit vaccine resulted in lower 
immunogenicity when tested in clinical trials [9-12]. Vaccination is one of the 
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most effective methods for preventing infectious diseases, and while the general 
immune response to vaccination is understood, the precise immunological 
mechanisms behind how vaccines work remain to be elucidated [13]. In the 
current study, we found that the 2009/2010 seasonal influenza subunit vaccine 
stimulated the immune system by binding to C-type lectin receptors and initiating 
signaling cascades that led to the production of pro-inflammatory cytokines, while 
the H5N1 vaccine bound C-type lectin receptors but did not initiate signaling. 
The current study demonstrated that mice immunized with the seasonal 
vaccine produced higher levels of both neutralizing antibodies and total vaccine 
specific IgG compared to mice immunized with the H5N1 vaccine (Figure 1). The 
results presented herein demonstrated that 86% of mice that received an IM 
vaccination of the seasonal influenza vaccine produced neutralizing antibodies at 
a titer greater than 1:40. This is comparable to data from human clinical trials in 
which 70% of vaccine recipients developed protective levels of neutralizing 
antibodies [11]. The production of low levels of vaccine specific total IgG in mice 
that received an IM immunization of the H5N1 vaccine demonstrated that vaccine 
specific antibodies are being produced, but they are non-functional. The quantity 
of vaccine specific total IgG produced by mice immunized with the H5N1 vaccine 
is still significantly lower than in mice immunized with the seasonal influenza 
vaccine. As a good cellular immune response leads to a good adaptive immune 
response, this data suggests that the mechanism behind the attenuated function 
of the H5N1 vaccine occurs earlier in the immune response prior to antibody 
production. The ability of seasonal influenza subunit vaccines to stimulate the 
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production of antibodies in mice, as demonstrated herein, is in agreement with 
previously reported studies [32, 33]. These studies, as well as others conducted 
in mice, also examine cellular responses following immunization and 
demonstrate that our model is sufficient for investigating the immune response to 
influenza vaccination [32-36].  
In the current study, BMDCs treated with seasonal influenza vaccine 
produced significantly higher levels of the pro-inflammatory cytokines IL-6, IL-12, 
and TNF-α compared to BMDCs treated with H5N1 vaccine, which did not induce 
cytokine production (Figure 2). The ability of the seasonal vaccine to induce 
cytokine expression in BMDCs is not surprising as previous studies, both in vivo 
and in vitro, have demonstrated that treatment with seasonal influenza subunit 
vaccines results in pro-inflammatory cytokine production [37-39]. The ability of 
the seasonal influenza vaccine to induce cytokine production demonstrates that 
the vaccine is able to stimulate APCs and initiate an immune response.  
Therefore, the absence of cytokine production by H5N1 vaccine treated BMDCs 
suggests that the HPAI vaccine is inefficient at activating APCs and results in 
attenuated immunogenicity. 
The production of the pro-inflammatory cytokines IL-6, IL-12, and TNF-α is 
the result of the activation of transcription factors such as NF-κB, AP-1, and 
IRF3/7 downstream of PRR stimulation [13, 15-18, 25, 40]. Influenza viruses are 
known to activate TLR3 which recognizes dsRNA and TLR7/8 which recognizes 
ssRNA [25-27]. The current study demonstrated that neither the seasonal 
influenza vaccine nor the H5N1 vaccine activated TLRs or NLRs (Figure 3). At 
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first this seemed surprising, but as the manufacturing process for influenza 
subunit vaccines ensures that only protein and no genetic material is left in the 
vaccine preparation [41, 42], it was understandable that TLRs recognizing 
genetic material were not activated. Interestingly, vaccine components did not 
activate other TLRs, such as TLR2 or TLR4 which recognize various proteins 
found on microbes [43-45]. NOD1 and NOD2 are most associated with the 
recognition of bacterial pathogens [46]; however, one study showed the 
importance of NOD2 in the recognition of ssRNA and respiratory syncytial virus 
(RSV) [47], while another study demonstrated that bacteria-infected mice co-
infected with murine norovirus displayed an augmentation in NOD1 and NOD2 
signaling and the subsequent production of pro-inflammatory cytokines [48]. 
Similar to TLRs, in the case of viral pathogens, NOD1/2 appears to be 
recognizing viral nucleic acid which explains the absence of activation in our 
model.           
As neither the seasonal vaccine nor the H5N1 vaccine activated TLRs or 
NLRs in the current study, CLRs were examined since the activation of these 
receptors also leads to the production of pro-inflammatory cytokines (Figure 2), 
and because CLRs have been identified as an important class of PRRs involved 
in antigen recognition and the initiation and regulation of the immune response to 
microbial infection [15, 18, 28-30]. Herein, pre-treatment of BMDCs with 
increasing concentrations of mannan (Figure 4) or mannose (Figure 5) led to a 
dose dependent decrease of pro-inflammatory cytokine production following 
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treatment with the seasonal influenza vaccine. This data implicates CLRs as the 
PRRs engaged by the seasonal influenza vaccine.  
CLRs recognize pathogens via mannose, fucose, and glucan 
carbohydrate structures present on microbes, with mannose being important for 
the recognition of viruses [15]. CLR activation results in receptor aggregation and 
subsequent signaling pathways are induced by two general mechanisms. CLRs 
such as Mincle, Dectin 2, BDCA2, and CLEC5A induce signaling through 
molecules that contain immunoreceptor tyrosine-based activation motifs (ITAMs) 
such as FcRy or DAP12. CLRs such as Dectin 1, DC-SIGN, DCIR, and 
CLEC12A induce signaling through the activation of protein kinases or 
phosphatases, such as Src family kinases and the recruitment of the kinase Syk, 
which interact with the cytoplasmic domains of the receptors [15, 18]. These 
mechanisms can influence the design of future studies aimed to identify the 
specific CLRs involved in influenza vaccine recognition.  
The HA, NA, and M2 surface proteins of the influenza virus are all targets 
of adaptive immunity [49], and the HA and NA proteins are the antigens present 
in the vaccine preparation [41]. The HA protein contains glycosylation sites [50] 
which could be recognized by CLRs. Interestingly, influenza viruses have not 
been shown to signal through CLRs; however, a recent study demonstrated that 
concurrent influenza infection and exposure to allergens resulted in an increase 
in CLR gene expression [51]. Our findings suggest that CLRs play an important 
role in immune recognition of inactivated subunit influenza vaccines.  
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In the current study, pre-treatment with increasing concentrations of either 
mannan or mannose resulted in a dose dependent decrease in cytokine 
production following treatment with the seasonal vaccine (Figures 4 and 5), 
providing a role for CLRs in vaccination against influenza. Following pre-
treatment with mannan, cells that were treated with H5N1 vaccine secreted 
roughly the same amount of cytokines as cells treated with mannan alone (Figure 
4). This data suggests that the H5N1 vaccine binds CLRs but does not initiate 
signaling. To substantiate this finding, BMDCs were pre-treated with increasing 
concentrations of H5N1 vaccine followed by treatment with either seasonal 
vaccine or mannan, and cytokine production again decreased in a dose 
dependent manner, confirming that the H5N1 vaccine is binding CLRs but not 
initiating a signaling cascade (Figure 6). These results provide a mechanism for 
the decreased immunogenicity of the H5N1 vaccine. The difference in the ability 
of the seasonal and H5N1 vaccines to activate CLRs suggests a variation in the 
glycosylation sites present on the HA proteins from the different viruses. Further 
studies elucidating the specific CLRs involved in influenza vaccine recognition 
will be important for advancing the knowledge behind the mechanisms of the 
immune response to influenza vaccines. Furthermore, identifying potential 
differences in glycosylation patterns on the HA proteins of the different viruses 
would contribute to the findings presented herein. 
The use of vaccines is imperative for the control of infectious diseases; 
however, the mechanisms behind vaccine immunogenicity are incompletely 
understood [13]. Identifying the means by which specific vaccines confer 
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protection from pathogens will lead to the development of more effective 
vaccines. Our findings, presented herein, elucidate a mechanism by which the 
2009/2010 seasonal influenza subunit vaccine gives rise to a protective antibody 
response whereas the H5N1 vaccine elicits an attenuated antibody response, 
and provide insight into the development of more immunogenic vaccines 
targeting HPAI.         
  
51 
 
 References 
1. Organization, W.H. Cumulative Number of Confirmed Human Cases of 
Avian Influenza A/(H5N1) Reported to WHO. 2012 04/26/0213 [cited 2013 
05/20/2013]; Available from: 
http://www.who.int/influenza/human_animal_interface/EN_GIP_20120607
CumulativeNumberH5N1cases.pdf. 
 
2. Mei, L., et al., Changes in and shortcomings of control strategies, drug 
stockpiles, and vaccine development during outbreaks of avian influenza 
A H5N1, H1N1, and H7N9 among humans. Bioscience trends, 2013. 7(2): 
p. 64-76. 
 
3. Baskin, C.R., et al., Early and sustained innate immune response defines 
pathology and death in nonhuman primates infected by highly pathogenic 
influenza virus. Proceedings of the National Academy of Sciences of the 
United States of America, 2009. 106(9): p. 3455-60. 
 
4. Sirinonthanawech, N., et al., Viral load of the highly pathogenic avian 
influenza H5N1 virus in infected human tissues. Journal of medical 
virology, 2011. 83(8): p. 1418-23. 
 
5. Yamaoka, M., et al., Virological surveillance of human influenza in 
Indonesia, October 2008-March 2010. Microbiology and immunology, 
2011. 55(7): p. 514-7. 
 
6. Dhere, R., et al., A pandemic influenza vaccine in India: From strain to 
sale within 12 months. Vaccine, 2011. 29 Suppl 1: p. A16-21. 
 
7. Suhardono, M., et al., Establishment of pandemic influenza vaccine 
production capacity at Bio Farma, Indonesia. Vaccine, 2011. 29 Suppl 1: 
p. A22-5. 
 
8. Services, F.G.U.S.D.o.H.H. National Strategy for Pandemic Influenza: 
Implementation Plan One Year Summary. 2007  [cited 2011 06/24/2011]; 
Available from: http://www.flu.gov/professional/federal/pandemic-
influenza-oneyear.pdf. 
 
9. Davies, J., Swine flu vaccines: reaching the finish line. Cell, 2009. 139(3): 
p. 449-51. 
 
10. Plennevaux, E., et al., Immune response after a single vaccination against 
2009 influenza A H1N1 in USA: a preliminary report of two randomised 
controlled phase 2 trials. Lancet, 2010. 375(9708): p. 41-8. 
52 
 
11. Xie, H., et al., Immunogenicity and cross-reactivity of 2009-2010 
inactivated seasonal influenza vaccine in US adults and elderly. PLoS 
ONE, 2011. 6(1): p. e16650. 
 
12. Treanor, J.J., et al., Safety and immunogenicity of an inactivated subvirion 
influenza A (H5N1) vaccine. The New England journal of medicine, 2006. 
354(13): p. 1343-51. 
 
13. Pulendran, B. and R. Ahmed, Immunological mechanisms of vaccination. 
Nature immunology, 2011. 12(6): p. 509-17. 
 
14. Aimanianda, V., et al., Novel cellular and molecular mechanisms of 
induction of immune responses by aluminum adjuvants. Trends in 
pharmacological sciences, 2009. 30(6): p. 287-95. 
 
15. Geijtenbeek, T.B. and S.I. Gringhuis, Signalling through C-type lectin 
receptors: shaping immune responses. Nature reviews. Immunology, 
2009. 9(7): p. 465-79. 
 
16. Iwasaki, A. and R. Medzhitov, Toll-like receptor control of the adaptive 
immune responses. Nature immunology, 2004. 5(10): p. 987-95. 
 
17. Kerrigan, A.M. and G.D. Brown, Syk-coupled C-type lectins in immunity. 
Trends in immunology, 2011. 32(4): p. 151-6. 
 
18. Kingeter, L.M. and X. Lin, C-type lectin receptor-induced NF-kappaB 
activation in innate immune and inflammatory responses. Cellular & 
molecular immunology, 2012. 9(2): p. 105-12. 
 
19. Rowe, T., et al., Detection of antibody to avian influenza A (H5N1) virus in 
human serum by using a combination of serologic assays. Journal of 
clinical microbiology, 1999. 37(4): p. 937-43. 
 
20. Lin, S.-C., et al., Recombinant Trimeric HA Protein Immunogenicity of 
H5N1 Avian Influenza Viruses and Their Combined Use with Inactivated 
or Adenovirus Vaccines. PLoS ONE, 2011. 6(5): p. e20052. 
 
21. Stout-Delgado, H.W., et al., Impaired NLRP3 inflammasome function in 
elderly mice during influenza infection is rescued by treatment with 
nigericin. Journal of immunology, 2012. 188(6): p. 2815-24. 
 
22. Kasturi, S.P., et al., Programming the magnitude and persistence of 
antibody responses with innate immunity. Nature, 2011. 470(7335): p. 
543-7. 
 
53 
 
23. Iwasaki, A. and R. Medzhitov, Toll-like receptor control of the adaptive 
immune responses. Nat Immunol, 2004. 5(10): p. 987-95. 
 
24. Hasan, U.A., G. Trinchieri, and J. Vlach, Toll-like receptor signaling 
stimulates cell cycle entry and progression in fibroblasts. The Journal of 
biological chemistry, 2005. 280(21): p. 20620-7. 
 
25. Garcia-Sastre, A., Induction and evasion of type I interferon responses by 
influenza viruses. Virus research, 2011. 162(1-2): p. 12-8. 
 
26. Fukuyama, S. and Y. Kawaoka, The pathogenesis of influenza virus 
infections: the contributions of virus and host factors. Current opinion in 
immunology, 2011. 23(4): p. 481-6. 
 
27. Wu, S., J.P. Metcalf, and W. Wu, Innate immune response to influenza 
virus. Current opinion in infectious diseases, 2011. 24(3): p. 235-40. 
 
28. Akira, S., Innate immunity and adjuvants. Philosophical transactions of the 
Royal Society of London. Series B, Biological sciences, 2011. 366(1579): 
p. 2748-55. 
 
29. den Dunnen, J., S.I. Gringhuis, and T.B. Geijtenbeek, Dusting the sugar 
fingerprint: C-type lectin signaling in adaptive immunity. Immunology 
letters, 2010. 128(1): p. 12-6. 
 
30. Svajger, U., et al., C-type lectin DC-SIGN: an adhesion, signalling and 
antigen-uptake molecule that guides dendritic cells in immunity. Cellular 
signalling, 2010. 22(10): p. 1397-405. 
 
31. Hudson, D.M., et al., Cystine-mediated oligomerization of the Atlantic 
salmon serum C-type lectin. Biochimica et Biophysica Acta (BBA) - 
Proteins and Proteomics, 2011. 1814(2): p. 283-289. 
 
32. Baldwin, S.L., et al., Enhanced humoral and Type 1 cellular immune 
responses with Fluzone adjuvanted with a synthetic TLR4 agonist 
formulated in an emulsion. Vaccine, 2009. 27(43): p. 5956-63. 
 
33. Coler, R.N., et al., A synthetic adjuvant to enhance and expand immune 
responses to influenza vaccines. PLoS ONE, 2010. 5(10): p. e13677. 
 
34. Segura-Velazquez, R., et al., Towards identification of the mechanisms of 
action of parasite-derived peptide GK1 on the immunogenicity of an 
influenza vaccine. Clinical and vaccine immunology : CVI, 2009. 16(9): p. 
1338-43. 
 
54 
 
35. Pang, I.K., T. Ichinohe, and A. Iwasaki, IL-1R signaling in dendritic cells 
replaces pattern-recognition receptors in promoting CD8(+) T cell 
responses to influenza A virus. Nature immunology, 2013. 14(3): p. 246-
53. 
 
36. Baz, M., et al., Effects of different adjuvants in the context of intramuscular 
and intranasal routes on humoral and cellular immune responses induced 
by detergent-split A/H3N2 influenza vaccines in mice. Clinical and vaccine 
immunology : CVI, 2012. 19(2): p. 209-18. 
 
37. Geeraedts, F., et al., Whole inactivated virus influenza vaccine is superior 
to subunit vaccine in inducing immune responses and secretion of 
proinflammatory cytokines by DCs. Influenza and other respiratory 
viruses, 2008. 2(2): p. 41-51. 
 
38. Saurwein-Teissl, M., et al., Whole virus influenza vaccine activates 
dendritic cells (DC) and stimulates cytokine production by peripheral blood 
mononuclear cells (PBMC) while subunit vaccines support T cell 
proliferation. Clinical and experimental immunology, 1998. 114(2): p. 271-
6. 
 
39. Weldon, W.C., et al., Effect of Adjuvants on Responses to Skin 
Immunization by Microneedles Coated with Influenza Subunit Vaccine. 
PLoS ONE, 2012. 7(7): p. e41501. 
 
40. Reinhard, K., et al., The role of NF-kappaB activation during protection 
against Leishmania infection. International journal of medical microbiology 
: IJMM, 2012. 302(4-5): p. 230-5. 
 
41. Pasteur, S., 271/371 Fluzone Package Insert, 2012: Swiftwater, PA. p. 13. 
 
42. Organization, W.H. Pandemic influenza vaccine manufacturing process 
and timeline. [Golbal Alert and Response: Pandemic (H1N1) 2009 briefing 
note 7] 2009  [cited 2013 05/30/2013]; Available from: 
http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en
/. 
 
43. Lee, H., et al., Toll-like receptors: sensor molecules for detecting damage 
to the nervous system. Current protein & peptide science, 2013. 14(1): p. 
33-42. 
 
44. Medvedev, A.E., Toll-Like Receptor Polymorphisms, Inflammatory and 
Infectious Diseases, Allergies, and Cancer. Journal of interferon & 
cytokine research : the official journal of the International Society for 
Interferon and Cytokine Research, 2013. 
55 
 
45. Wang, X., C. Smith, and H. Yin, Targeting Toll-like receptors with small 
molecule agents. Chemical Society reviews, 2013. 42(12): p. 4859-66. 
 
46. Moreira, L.O. and D.S. Zamboni, NOD1 and NOD2 Signaling in Infection 
and Inflammation. Frontiers in immunology, 2012. 3: p. 328. 
 
47. Sabbah, A., et al., Activation of innate immune antiviral responses by 
Nod2. Nature immunology, 2009. 10(10): p. 1073-80. 
 
48. Kim, Y.G., et al., Viral infection augments Nod1/2 signaling to potentiate 
lethality associated with secondary bacterial infections. Cell host & 
microbe, 2011. 9(6): p. 496-507. 
 
49. Suarez, D.L. and S. Schultz-Cherry, Immunology of avian influenza virus: 
a review. Developmental and comparative immunology, 2000. 24(2-3): p. 
269-83. 
 
50. Job, E.R., et al., Addition of glycosylation to influenza A virus 
hemagglutinin modulates antibody-mediated recognition of H1N1 2009 
pandemic viruses. Journal of immunology, 2013. 190(5): p. 2169-77. 
 
51. Al-Garawi, A., et al., Shifting of immune responsiveness to house dust 
mite by influenza A infection: genomic insights. Journal of immunology, 
2012. 188(2): p. 832-43. 
 
  
56 
 
Figure Legends 
Figure 1. Increase in vaccine specific antibody responses in BALB/c mice 
vaccinated with seasonal influenza vaccine but not HPAI vaccine. Male 
BALB/c mice were given either a subcutaneous (SC) or intramuscular (IM) 
injection of seasonal vaccine, HPAI vaccine, or saline. Sera were collected 3 
weeks later and antibody titers determined by neutralization assay or ELISA. A. 
Neutralizing antibody titers in mice treated with seasonal vaccine SC (squares), 
HPAI vaccine SC (triangles), seasonal vaccine IM (circles), or HPAI vaccine IM 
(upside down triangles). Error bars indicate mean ± SEM (*p<.05, **p<.005, 
Student’s t-test). B. Total vaccine specific IgG as determined by ELISA in mice 
treated with saline IM (closed circles), saline SC (squares), seasonal SC 
(triangles), HPAI SC (upside down triangles), seasonal IM (diamonds), or HPAI 
IM (open circles). Error bars indicate mean ± SEM (*p<.05, **p<.001, ***p<.0001, 
Student’s t-test). 
 
Figure 2. Increased cytokine production after treatment of BMDCs with 
seasonal vaccine but not HPAI vaccine. BMDCs were treated with seasonal 
vaccine (checkered bars), HPAI vaccine (white bars), LPS (striped bars), or 
media alone (black bars) for 24 hours. Cytokine production was determined by 
ELISA. A. IL-6 production in vaccine treated BMDCs expressed as mean ± SEM 
(***p<.0005, Student’s t-test). B. IL-12 production by vaccine treated BMDCs 
expressed as mean ± SEM (**p<.005, Student’s t-test). C. TNF-α production in 
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vaccine treated BMDCs expressed as mean ± SEM (****p<.0001, Student’s t-
test). Results represent three independent experiments. 
 
Figure 3. Neither vaccine stimulates Toll-like or NOD-like receptors. THP1-
XBlue reporter monocytes expressing TLRs 1-9 and NOD1/2 transfected with 
SEAP were treated with seasonal vaccine (checkered bars), HPAI vaccine (white 
bars), LPS (striped bars), HKLM (diagonal bars), or media alone (black bars) for 
24 hours. Cell supernatants were then incubated in the presence of QUANTI-
Blue for 2 hours and SEAP expression was determined using a 
spectrophotometer. LPS was used as a positive control for TLR4 and HKLM was 
used as a positive control for TLR2. Results represent two independent 
experiments.    
 
Figure 4. Influenza vaccines bind the same receptors as mannan. BMDCs 
were pre-treated with increasing concentrations of mannan followed by treatment 
with either seasonal influenza vaccine or HPAI vaccine for 24 hours, and 
cytokine production was assessed by ELISA. A. IL-6 production by vaccine 
treated BMDCs pre-treated with increasing concentrations of mannan (p<.0001, 
Two-way ANOVA comparing all groups). B. IL-12 production by vaccine treated 
BMDCs pre-treated with increasing concentrations of mannan (p<.0001, Two-
way ANOVA comparing all groups). C. TNF-α production by vaccine treated 
BMDCs pre-treated with increasing concentrations of mannan (p<.0001, Two-
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way ANOVA comparing all groups). Results represent two or more independent 
experiments.  
 
Figure 5. The seasonal influenza vaccine signals through C-type lectin 
receptors. BMDCs were pre-treated with increasing concentrations of mannose 
followed by treatment with either seasonal vaccine or HPAI vaccine for 24 hours, 
and cytokine production was assessed by ELISA. A. IL-6 production by vaccine 
treated BMDCs pre-treated with increasing concentrations of mannose (p<.0001, 
Two-way ANOVA comparing all groups). B. IL-12 production by vaccine treated 
BMDCs pre-treated with increasing concentrations of mannose (p<.0001, Two-
way ANOVA). C. TNF-α production by vaccine treated BMDCs pre-treated with 
increasing concentrations of mannose (p<.0001, Two-way ANOVA). Results 
represent two independent experiments.  
 
Figure 6. HPAI vaccine binds C-type lectin receptors without signaling. 
BMDCs were pre-treated with increasing concentrations of HPAI vaccine 
followed by treatment with either seasonal vaccine or mannan for 24 hours, and 
cytokine expression was assessed by ELISA. A. IL-6 production by vaccine 
treated BMDCs pre-treated with increasing concentrations of HPAI vaccine 
(p<.05, Two-way ANOVA comparing all groups). B. IL-12 production by vaccine 
treated BMDCs pre-treated with increasing concentrations of HPAI vaccine 
(p<.0005, Two-way ANOVA comparing all groups). C. TNF-α production by 
vaccine treated BMDCs pre-treated with increasing concentrations of HPAI 
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vaccine (p<.0005, Two-way ANOVA comparing all groups). Results were 
obtained from two independent experiments.
60 
 
Figures 
Figure 1 
61 
 
Figure 2 
 
62 
 
Figure 3 
 
63 
 
Figure 4 
 
64 
 
Figure 5 
 
65 
 
Figure 6 
 
  
66 
 
CHAPTER THREE: 
Alum adjuvant rescues HPAI vaccine immunogenicity and survival in 
BALB/c mice by facilitating increased antigen uptake and intracellular 
processing 
 
Sarah E. Vaughan1,2, Heather W. Stout-Delgado1, Zemmie E. Pollock1, Jennifer 
R. Plourde1,2, John A. Pyles1, Zachary S. Karim 1,2, Bridget S. Wilson, and Kevin 
S. Harrod1,# 
 
1Infectious Diseases Program, Lovelace Respiratory Research Institute, 
Albuquerque, NM, 87108 
 
2Biomedical Sciences Graduate Program, University of New Mexico, 
Albuquerque, NM, 87131 
 
# Email:kharrod@lrri.org 
 
Conceived and designed experiments: SEV, HWS, BSW, KSH.  Performed the 
experiments: SEV, HWS, ZEP, JRP, JAP, ZAK.  Analyzed the data: SEV, HWS, 
KSH.  Wrote the paper: SEV, KSH. 
  
67 
 
Abstract 
Highly pathogenic avian influenza (HPAI) H5N1 is an emerging infectious 
virus with an approximate 60% fatality rate in humans. In the United States, a 
vaccine for H5N1 has been developed and stockpiled in case of a pandemic; 
however, the vaccine demonstrated low immunogenicity in clinical trials. 
Adjuvants can be used to enhance the immune response to antigens. In this 
study, we examined differences in the immune response to the H5N1 vaccine 
with or without the addition of an alum adjuvant in a lethal challenge mouse 
model of HPAI infection. Mice treated with the adjuvanted vaccine displayed 
significantly reduced weight loss, increased survival, and higher neutralizing 
antibody titers compared to mice treated with the non-adjuvanted vaccine. 
Dendritic cells (DCs) cultured with the adjuvanted vaccine displayed increased 
expression of the activation markers CD40, CD86, and MHC II compared to DCs 
treated with the non-adjuvanted vaccine. DCs treated with HPAI vaccine with or 
without alum adjuvant did not produce pro-inflammatory cytokines nor signal 
through the NLRP3 inflammasome. When treated with the adjuvanted vaccine, 
DCs demonstrated increased vaccine uptake and phagosomal activity compared 
to those treated with the non-adjuvanted vaccine. Our study demonstrates that 
the alum adjuvant rescues vaccine immunogenicity and improves survival in the 
host by facilitating increased antigen uptake and intracellular processing, and 
provides insight into the development of more immunogenic vaccines targeting 
HPAI. 
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Introduction 
Highly pathogenic avian influenza (HPAI) H5N1 viruses typically infect 
avian species but are extremely lethal in humans. Symptoms include fast 
progressing pneumonia, respiratory distress syndrome, damage to the central 
nervous system, and multi-organ failure [1, 2]. These viruses have resulted in 
more than 600 human infections documented in 15 countries since 2003, and 
have had an approximate 60% fatality rate with death usually occurring 10 days 
after symptom onset in fatal cases [1-4]. Despite the emergence of a novel H7N9 
avian influenza outbreak in humans, H5N1 cases continue and little evidence 
exists suggesting that H5N1 prevalence has abated. Currently, transmission 
between humans is sporadic; however, enhanced transmission though viral 
adaptation is plausible thus making an H5N1pandemic feasible [4-6].    
In preparation for a pandemic, the United States government stockpiled 20 
million doses of an inactivated subunit vaccine for HPAI; however, this vaccine 
resulted in low immunogenicity in human clinical trials with only 22% of recipients 
developing protective antibody titers of 1:40 or greater [7, 8]. Previous studies in 
our laboratory, using a lethal challenge ferret model of HPAI infection, 
demonstrated that the HPAI vaccine provided only limited protection with 0%-
64% survival depending on the dose administered. When an alum adjuvant was 
added to the HPAI vaccine, survival improved significantly to 93%, and the 
vaccine was safe and well tolerated [9].   
Adjuvants are substances that can influence and enhance the immune 
response to antigens [10]. Vaccines that contain purified antigen, rather than 
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intact pathogens, often contain adjuvants in order to amplify the immune 
response to the vaccine [11]. The most commonly used adjuvant in vaccines 
worldwide is alum, a mixture of aluminum salts [10, 12, 13]. The mechanism by 
which alum functions as an adjuvant remains controversial and unclear with 
multiple possible mechanisms described [14-17]. One proposed theory is that 
alum binds to vaccine components causing them to be slowly released to the 
immune system over time [10, 11]. Some reports have shown that alum can also 
work by activating the NLRP3 inflammasome immune complex, while others 
have shown that this is not the primary mechanism of action for alum [14, 18].  
Additionally, previous studies have demonstrated that alum increases antigen 
internalization by dendritic cells (DCs) through binding to cell membrane lipids 
thereby triggering an endocytic response and signaling cascades that result in 
CD4+ T cell activation and humoral immune responses [15-17].   
Herein, immunization in a lethal challenge mouse model was utilized to 
elucidate the mechanism by which alum enhances HPAI vaccination.  We show 
that, in vivo, the addition of alum to the HPAI vaccine increased neutralizing 
antibody titers and survival in BALB/c mice, while in vitro, treatment with the 
adjuvanted vaccine resulted in up-regulation of the cell surface markers CD40, 
CD86, and MHC II on DCs. Surprisingly, the addition of an alum adjuvant to the 
HPAI vaccine did not induce NLRP3 inflammasome activation nor production of 
pro-inflammatory cytokines. Furthermore, the addition of alum to the H5N1 
vaccine increased antigen uptake and intracellular processing in DCs. Our 
results indicate that the H5N1 split virion vaccine is unable to induce an early 
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antigenic response in APCs, but this can be overcome by the addition of an alum 
adjuvant.  
 
Materials and Methods 
Mice 
Male BALB/c mice, aged six to eight weeks, were purchased from the 
National Cancer Institute at Frederick (NCI-Frederick, Bethesda, MD), and held 
for 21 days for quarantine and acclimation.  Mice were housed four per cage in 
microisolator cages under identical husbandry conditions and fed certified 
commercial feed. Animals were identified by BMDS microchips (IPTT-300 
Implantable Programmable Temperature and Identification Transponder from Bio 
Medic Data System, Inc. (BMDS) Seaford, DE) inserted subcutaneously between 
the shoulder blades, and cage cards. All animal studies were approved by the 
Lovelace Respiratory Research Institute Institutional Animal Care and Use 
Committee.   
 
Vaccines 
The following reagent was obtained through the National Institutes of 
Health (NIH) Biodefense and Emerging Infections (BEI) Research Resources 
Repository, NIAID, NIH: Monovalent Influenza Subvirion Vaccine, 
rg/A/Vietnam/1203/2004, NR-4143 at a concentration of 30ug/ml hemagglutinin 
protein. Adjuvanted H5N1 Monovalent Influenza subvirion vaccine, 
rg/A/Vietnam/1203/2004, with a proprietary concentration of alum adjuvant was 
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provided under contract from DMID/NIAID/NIH at two concentrations of 
hemagglutinin (HA) protein: 45ug/ml (lot UD07828) and 15ug/ml (lot UD07826), 
or was prepared by research staff at a concentration of 1200ug alum (Invitrogen, 
Grand Island, NY) per 1 ml of the provided non-adjuvanted vaccine [19].  
Vaccines were diluted to 0.6ug/ml HA protein with 0.05ml physiological saline 
immediately prior to vaccination.    
 
Virus 
Influenza virus A/Vietnam/1203/2004 (VN1203) subtype H5N1 was 
obtained from the Centers for Disease Control and Prevention (Atlanta, GA) as 
low-passage stock. The virus was passaged once in 10-day old embryonated 
chicken eggs to generate the master stock and then twice in eggs to generate 
the virus for all subsequent uses. Aliquots of 0.5ml to 1ml were stored at -80°C.  
After storage, the virus was determined to have a concentration of 1.4 x 108 
plaque forming units (pfu/ml), 5.8 x 108 50% tissue culture dose (TCID50/ml), and 
1 x 108 50% egg infectious dose (EID50/ml). Influenza A/Vietnam/1203/2004 is a 
Risk Group 3 pathogen and all experiments involving this virus were carried out 
in a Biosafety Level 3 (BSL 3) containment facility at the Lovelace Respiratory 
Research Institute and approved by the Institutional Biosafety Committee.  
 
Immunization and Viral Challenge 
Mice (n = 6 per group) were given a primary or a primary and secondary 
intramuscular injection in the gastrocnemius muscle of the H5N1 vaccine with or 
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without alum adjuvant. Secondary vaccinations were administered three weeks 
following primary vaccinations. Control animals received intramuscular injections 
of 0.05ml physiological saline. Seven weeks following primary vaccination, mice 
were challenged intranasally (IN) with a lethal dose (10 pfu) of 
A/Vietnam/1203/2004 (VN1203), and morbidity and mortality were assessed. 
Twice daily observations were conducted to determine animal health by 
appearance and activity. The injection site was monitored for inflammation and 
irritation. Body temperatures and bodyweights were recorded before vaccination, 
weekly prior to challenge, and daily thereafter. Animals were considered 
moribund if they experienced greater than 15% weight loss. 
 
Serology 
Blood for serum was collected from mice at necropsy by cardiac puncture 
three weeks after primary vaccination or four weeks after secondary vaccination.  
Blood was placed in serum separator collection tubes and incubated at room 
temperature for 30 minutes before centrifugation at 2500rpm for 10 min. Serum 
was collected and stored at -20°C until analyzed. The neutralization assay was 
modified from previously described procedures [20]. Briefly, serum samples were 
treated with receptor-destroying enzyme (Enka-Seiken, Tokyo, Japan) at a ratio 
of 1:1 followed by heat inactivation at 56°C for 45 minutes. The serum samples 
were incubated with 2 x 103 TCID50 A/Vietnam/1203/2004 at 37°C for one hour.  
After incubation, Madin-Darby Canine Kidney (MDCK) cells plated in 96 well 
plates were inoculated in triplicate with the samples using a 2-fold dilution and 
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incubated at 37°C for three days. The plates were then scored for cytopathic 
effect (CPE), and neutralizing antibody titers were determined as the highest 
serum dilution at which no CPE occurred [9, 21]. 
 
Primary Bone Marrow Cell Isolation, Culture, and Treatment 
Bone marrow cells were collected and cultured as previously described 
[22]. Briefly, bone marrow cells were isolated from the femurs and tibiae of mice 
and cultured in complete RPMI media (Invitrogen, Carlsbad, CA) containing 10% 
FBS (Invitrogen), 1x penicillin/streptomycin (Invitrogen), and 25ng/ml GM-CSF 
(Cell Signal Technology, Danvers, MA) for 5-7 days at 37°C with 5% CO2. The 
following treatments were given in complete RPMI for 2 or 24 hours for in vitro 
experiments: 0.6ug/ml (HA protein) of non-adjuvanted HPAI vaccine; 0.6ug/ml 
(HA protein) of adjuvanted HPAI vaccine; 250ug/ml alum (Invivogen, San Diego, 
CA). 
 
Treatment with Acridine Orange   
Evaluation of phagosomal activity was assessed using modifications to 
previously described procedures [23]. BMDCs cultured as described above were 
pre-treated with 0.5ug/ml acridine orange (Invitrogen) for 15 min at 37°C prior to 
above treatments for select experiments and analyzed by flow cytometry.   
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Treatment with FITC Conjugated HPAI Vaccine 
The adjuvanted and non-adjuvanted HPAI vaccines were conjugated to 
FITC (Thermo Scientific, Waltham, MA) using modifications to previously 
described procedures and the manufacturer’s instructions [24]. Briefly, 15- to 20- 
fold molar excess of FITC was added to one vial of vaccine and incubated at 
room temperature for one hour in the dark. Excess and hydrolyzed FITC was 
removed by dye column removal kits (Thermo Scientific). BMDCs cultured as 
described above were treated with the FITC conjugated vaccine for 2 hours and 
analyzed by flow cytometry. For microscopy experiments, Armenian hamster 
anti-mouse CD11c clone N418 conjugated to PE-Cy7 (eBioscience, San Diego, 
CA) was used as a cell surface marker. 
 
Flow Cytometry 
In vitro experiments for cell surface marker expression, as well as those 
using acridine orange pre-treated cells, and cells treated with the FITC 
conjugated vaccines were analyzed by flow cytometry. Antibodies utilized 
include: Armenian hamster anti-mouse/rat CD40 clone HM40-3 conjugated to 
FITC (eBioscience); rat anti-mouse CD86 clone GL1 conjugated to PE 
(eBioscience); and  rat anti-mouse MHC II I-A/I-E clone M5/114.15.2 conjugated 
to PerCP/Cy5.5 (BioLegend, San Diego, CA). Samples were run on a FACS 
Canto flow cytometer (BD Bioscience, San Jose, CA) and analyzed by FlowJo 
cytometry analysis software (TreeStar, Ashland, OR). Cell populations were 
gated on viable cells and assessed for expression in the FL1 (CD40 and FITC), 
75 
 
FL2 (CD86), or FL3 (MHC II and acridine orange) channels. Compensation was 
calculated using BD CompBeads (BD Bioscience). For each experiment, treated 
cells were compared to cells in culture media alone. 
 
ELISA 
BMDC culture supernatants were analyzed for IL-6, IL-12, IL-1β, and TNF-
α production using ELISA kits purchased from eBioscience according to the 
manufacturer’s instructions. 
 
Widefield Fluorescence Microscopy 
Images were acquired on an Olympus IX81 microscope using an LCAch N 
40x/0.55 air UIS2m objective. Acridine orange was imaged using a 452 dichroic 
and a 520-550 emission filter. FITC was imaged using a 495 dichroic and a 
502.5-537.5 emission filter. CD11c-PE-Cy7 was imaged using a 760 dichroic and 
a 765-855 emission filter. Acquisition was done using Metamorph (Molecular 
Devices, Sunnyvale, CA), and image processing done using ImageJ (National 
Institutes of Health, Bethesda, MD.). 
 
Statistical Analysis 
Bodyweights, body temperatures, and neutralizing antibody titers are 
expressed as mean values from each group of n = 6 mice. All statistical analysis 
was completed using the analysis software included in GraphPad Prism 
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(GraphPad Prism 5 for Windows, version 5.03; GraphPad Software, Inc., La 
Jolla, CA.).   
 
Results 
Morbidity and Mortality Following HPAI Challenge in Vaccinated Mice 
Previous studies have shown that the subunit vaccine targeting H5N1 is 
not protective in a lethal challenge ferret model unless supplemented with an 
alum adjuvant [9]. As limited immunologic reagents are available for exploring 
molecular mechanisms in ferrets, we examined the immune response to H5N1 
vaccination in a lethal challenge BALB/c mouse model of H5N1 infection. To 
assess protection conferred by the HPAI vaccine, BALB/c mice (n=6 per group) 
were given a primary intramuscular (IM) vaccination of the HPAI vaccine (0.6ug) 
with or without an alum adjuvant, and challenged intranasally (IN) with a lethal 
dose (10 pfu) of A/Vietnam/1203/2004 (VN1203) 7 weeks following vaccination.  
Non-vaccinated challenged control mice began losing weight 3 days post 
infection (dpi) (Figure 1a), and mortality began 5 dpi with 100% mortality 
occurring by 7 dpi (Figure 1b). Mice that received the non-adjuvanted vaccine 
began losing weight 4 dpi and weight loss peaked 7 dpi before recovering in 
surviving animals. Mortality in mice that received the non-adjuvanted vaccine 
began 6 dpi with 33% of animals surviving. Mice that received the adjuvanted 
vaccine had similar weight loss initially to those that received the non-adjuvanted 
vaccine beginning 4 dpi; however, weight loss did not progress in this group 
beyond 5 dpi. Animals that received the adjuvanted vaccine achieved 83% 
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survival with one death 8 dpi. Non-vaccinated, non-challenged control animals 
exhibited steady bodyweights and had 100% survival as expected. Taken 
together, these results demonstrate that the addition of an alum adjuvant to the 
HPAI vaccine provides greater protection in BALB/c mice, and these results are 
similar to those observed previously in a ferret model [9]. 
 
Neutralizing Antibody Titers in Vaccinated Mice 
To evaluate differences in the production of functional antibody titers to 
HPAI in vaccine treated animals, BALB/c mice (n=6 per treatment) received a 
primary or a primary and secondary IM vaccination of 0.6ug of the HPAI vaccine 
with or without the addition of an alum adjuvant. Antibody titers were assessed 
by neutralization assay 21 days following primary vaccination and 28 days 
following secondary vaccination. Neutralizing antibody titers were observed in 
50% of mice that received a primary vaccination of the adjuvanted HPAI vaccine, 
but were below the level considered protective (>1:40). Neutralizing antibodies 
were not detected in mice that received a primary vaccination of the non-
adjuvanted HPAI vaccine (Figure 2a). All mice that received a primary and 
secondary vaccination of either the adjuvanted or non-adjuvanted HPAI vaccine 
developed neutralizing antibody titers. Of the mice that received the adjuvanted 
vaccine, 83% developed antibody titers greater than 1:40, whereas only 33% of 
mice that received the non-adjuvanted vaccine developed antibody titers greater 
than 1:40. Neutralizing antibody titers in mice that received the adjuvanted 
vaccine were significantly higher compared to mice that received the non-
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adjuvanted vaccine (Figure 2b). These results illustrate that the addition of an 
alum adjuvant increased neutralizing antibody titers against VN1203 in BALB/c 
mice.  
 
Dendritic Cell Activation Following Vaccine Treatment 
It is recognized that an effective innate immune response contributes to a 
functional adaptive immune response, and dendritic cells (DCs) are well 
established as antigen presenting cells. The ability of DCs to process antigen 
and drive T cell responses makes them an important cell type in vaccination, and 
many vaccines are being developed to specifically target DCs [25-27]. Upon 
activation, DCs up-regulate the expression of cell surface markers such as 
CD40, CD80/86, and MHC II [28]. We examined differences in DC activation 
following treatment with the HPAI vaccine with or without alum adjuvant in vitro.  
Bone marrow derived dendritic cells (BMDCs) were treated with either the 
adjuvanted or non-adjuvanted HPAI vaccines, and stained for the cell surface 
activation markers CD40, CD86, and MHC II. BMDCs treated with adjuvanted 
HPAI vaccine showed increased expression of CD40, with approximately 60% 
positive (Figure 3a and d), CD86 (55% positive) (Figure 3b and e), and MHC II 
(80% positive) (Figure 3c and f) compared to BMDCs treated with the non-
adjuvanted HPAI vaccine and relative to non-treated cells in media alone. Cell 
surface marker expression on BMDCs treated with the non-adjuvanted HPAI 
vaccine was similar to expression on non-treated cells, and treatment with alum 
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alone did not result in the up-regulation of cell surface marker expression (data 
not shown). 
Antigen recognition by DCs can also result in intracellular signaling 
cascades that lead to the secretion of pro-inflammatory cytokines such as IL-6, 
IL-12, TNF-α, and IL-1β [29-31]. Alum has been previously shown to stimulate 
the NLRP3 inflammasome pathway resulting in pro-inflammatory and anti-
microbial responses. Inflammasome activation is characterized by the secretion 
of the pro-inflammatory cytokines IL-1β and IL-18 [14, 32]. To assess whether 
alum is inducing inflammasome involvement in response to H5N1 vaccination, 
murine bone marrow derived dendritic cells (BMDCs) were treated with either the 
adjuvanted or non-adjuvanted HPAI vaccine and cell culture supernatants were 
collected and assessed for the expression of the cytokine IL-1β by ELISA. LPS + 
ATP was used as a positive control and produced a robust IL-1β response. When 
treated with either the adjuvanted or non-adjuvanted HPAI vaccines, BMDCs did 
not secrete IL-1β (Figure 4a). These results suggest that the mechanism of 
action of alum in this system is not NLRP3 inflammasome pathway activation.  
To further assess whether vaccine stimulation resulted in pro-inflammatory 
responses, cell culture supernatants from vaccine-treated BMDCs were analyzed 
for the production of the cytokines IL-6, IL-12, and TNF-α by ELISA. LPS was 
used as a positive control and resulted in the secretion of high levels of all three 
pro-inflammatory cytokines. Surprisingly, the HPAI vaccine with or without the 
addition of an alum adjuvant failed to induce the production of these cytokines 
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(Figure 4b-d). These results demonstrate that neither vaccine stimulated 
signaling pathways that lead to pro-inflammatory cytokine secretion.            
 
Vaccine Uptake and Intracellular Processing 
A recent study has shown that alum can function as an adjuvant by 
directly promoting antigen uptake by DCs [15]. To determine if alum is 
functioning in this manner in this model, we next examined the ability of BMDCs 
to take up the HPAI vaccine with or without alum adjuvant. Briefly, BMDCs were 
treated with FITC-conjugated, adjuvanted or non-adjuvanted vaccine for two 
hours. FITC expression was measured and quantified using flow cytometry 
(Figure 5a and b). BMDCs treated with the adjuvanted vaccine demonstrated a 
clear increase in FITC expression compared to BMDCs treated with the non-
adjuvanted vaccine (Figure 5a). Fluorescence intensity was quantified and 
increased by 10-fold in cells treated with the adjuvanted vaccine compared to 
cells treated with the non-adjuvanted vaccine (Figure 5b). Vaccine uptake was 
further assessed by fluorescent microscopy, and BMDCs treated with the FITC-
conjugated, adjuvanted HPAI vaccine revealed more intense fluorescence 
compared to cells treated with the non-adjuvanted vaccine (Figure 5c).   
To assess differences in antigen processing following vaccine uptake, we 
examined phagosomal activity post vaccine treatment using acridine orange 
quenching. The dye acridine orange has been used previously to examine 
activity within acidic cellular compartments [23, 33, 34]. Acridine orange becomes 
highly concentrated in acidic cellular compartments and is sensitive to changes in 
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pH; therefore, fluorescence quenching can be used to quantify phagosomal 
activity [23]. BMDCs were pre-treated with acridine orange followed by treatment 
with the HPAI vaccine with or without adjuvant for 2 hours. Cells were collected 
and analyzed by fluorescence microscopy and flow cytometry, and phagosomal 
activity was observed as a decrease in acridine orange expression. Cells treated 
with alum, acridine orange alone, or non-adjuvanted HPAI vaccine expressed 
high levels of acridine orange, suggesting little activity in phagosomal processing. 
Cells treated with adjuvanted HPAI vaccine had decreased acridine orange 
fluorescence compared to the other treatments, indicating an increase in 
phagosomal activity (Figure 6a-c). Taken together, these results illustrate that the 
addition of an alum adjuvant to the HPAI vaccine results in increased vaccine 
uptake by BMDCs, which in turn, results in increased intracellular processing, 
when compared to BMDCs treated with the non-adjuvanted HPAI vaccine.       
 
Discussion 
An inactivated subunit vaccine targeting H5N1 resulted in low 
immunogenicity when evaluated in human clinical trials [7]; however, studies 
conducted in a lethal challenge ferret model demonstrated that the addition of an 
alum adjuvant to the H5N1 vaccine resulted in increased survival and functional 
antibody production [9]. The mechanism of action of alum as an adjuvant is 
multifaceted and controversial [14-17]. In the current study, we found that alum 
enhances the immune response to the H5N1 vaccine by facilitating increased 
antigen uptake and intracellular processing. The addition of alum to the HPAI 
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vaccine resulted in decreased morbidity and mortality in a lethal challenge mouse 
model (Figure 1), as well as the increased production of neutralizing antibodies in 
vaccinated animals (Figure 2). These results coincide with previous findings in 
ferrets, and show that our model is sufficient for studying the immune response 
to HPAI vaccination [9]. The ferret model is less suited to study the immune 
response as limited immunological reagents are available.   
In the current study, BMDCs treated with the alum-adjuvanted HPAI 
vaccine had increased expression of the co-stimulatory markers CD40, CD86, 
and MHC II compared to cells treated with the non-adjuvanted HPAI vaccine 
(Figure 3), which demonstrates that the addition of alum to the vaccine 
preparation led to the activation of APCs. These results were expected as 
previous studies have shown the ability of alum, when in the presence of antigen, 
to upregulate CD40, CD86, and MHC II on monocytes and macrophages [35-38]. 
The activation of APCs and the subsequent upregulation of co-stimulatory 
molecules on the cell surface are critical for the presentation of antigen to T cells 
and the progression of a productive immune response [28, 35].      
While our data demonstrated that the addition of alum to the HPAI vaccine 
was able to activate DCs, neither treatment with adjuvanted nor non-adjuvanted 
vaccine resulted in the production of the pro-inflammatory cytokines IL-6, IL-12, 
or TNF-α (Figure 4b-d). While previous studies have shown that alum alone does 
not induce expression of these cytokines, as they are associated with TH1 
responses and not TH2 responses [11, 14], it is interesting that other vaccine 
components did not initiate cytokine production. An in vivo study of influenza 
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vaccination in mice demonstrated that vaccination with a seasonal influenza 
subunit vaccine resulted in the production of the cytokines IL-6 and TNF-α in the 
lungs [39]. In vitro, a study in mice showed that following treatment with a subunit 
seasonal influenza vaccine, DCs produced low levels of IL-6 and TNF-α, but no 
detectable IL-12 [40], while another study detected low levels of TNF-α but no 
detectable IL-12 from DCs isolated from human PBMCs and treated with a 
subunit seasonal influenza vaccine [41]. Together, these studies demonstrate 
that cytokine production by APCs following vaccination with subunit seasonal 
influenza vaccines in vivo can be expected, while, in vitro, production of the 
cytokines IL-6 and TNF-α by vaccine treated DCs is less pronounced but still 
detectable. This suggests that the HPAI vaccine used in our study is less efficient 
than the seasonal influenza subunit vaccines in activating DCs.   
In addition to IL-6, IL-12, and TNF-α, BMDCs treated with the alum-
adjuvanted HPAI vaccine did not produce IL-1β (Figure 4a). This was surprising 
as alum has been previously shown to signal through the NLRP3 inflammasome 
complex, and the production of IL-1β is a result of activating this immune 
complex [14, 32]. The lack of inflammasome involvement in our study could be 
explained by the fact that inflammasome activation and the subsequent 
production of IL-1β require two signals. Alum is known to provide the second 
signal, which directly activates Nlrp3. The first signal is provided by endogenous 
or microbial antigens that activate NF-κB [14, 32]. It appears that, in our study, 
following treatment with the alum-adjuvanted HPAI vaccine, the first signal is 
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missing. This idea is supported by the lack of production of IL-6, IL-12, and TNF-
α, which are downstream of NF-κB activation [42].  
Herein, alum was able to facilitate increased antigen uptake in vaccine 
treated BMDCs (Figure 5). This finding is supported by a previous study that 
demonstrated an inflammasome independent mechanism of action for alum, in 
which alum acts as an adjuvant by binding to the plasma membrane of DCs and 
activating endocytic uptake via delayed ERK phosphorylation leading to antigen 
uptake [15]. The authors demonstrated that alum interacts with membrane lipids 
on the surface of DCs, which results in the aggregation of ITAM-containing 
receptors and subsequent Syk and PI3K signaling, and further demonstrated that 
while allowing antigen uptake by DCs, alum itself did not enter the cell. The 
findings from the current study suggest that this is the mechanism of action 
employed by alum with regard to increased H5N1 vaccine immunogenicity.  
Following increased antigen uptake by vaccine treated BMDCs, an 
increase in antigen processing was demonstrated using acridine orange staining 
in BMDCs treated with the adjuvanted vaccine compared to those treated with 
the non-adjuvanted vaccine (Figure 6). This finding is consistent with the idea 
that if an increased amount of antigen is internalized by the cell that an increased 
amount of antigen processing will occur. This increase in antigen processing 
coincides with the upregulation of MHC II on the cell surface of BMDCs treated 
with the adjuvanted vaccine compared to those treated with the non-adjuvanted 
vaccine (Figure 3).   
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Taken together, our data suggests that the H5N1 vaccine examined in this 
study is unable to efficiently stimulate DCs without the addition of an adjuvant. 
The addition of alum to the vaccine preparation allows increased antigen uptake, 
possibly through an endocytic response, and subsequently, increased antigen 
processing. Further studies conducted in vivo of the immune mechanisms 
demonstrated by the current study would contribute to the findings presented 
herein. Vaccination is one of the most effective methods for preventing infectious 
diseases, and while the general immune response to vaccination is understood, 
the precise mechanisms behind the ability of vaccines to stimulate the immune 
system and lead to long term protection remain to be elucidated [30]. Identifying 
the mechanisms by which vaccines confer protection from disease will allow 
more effective vaccines to be developed. This is particularly important for 
pathogens for which current vaccines are not available or not sufficient, as is the 
case with highly pathogenic avian influenza. Our findings, presented herein, 
elucidate a mechanism by which the H5N1 vaccine offers only limited protection, 
and provide insight into the development of more immunogenic vaccines 
targeting HPAI.   
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Figure Legends 
Figure 1. Morbidity and mortality was decreased in BALB/c mice following 
vaccination with adjuvanted HPAI vaccine. BALB/c mice (n=6 per group) were 
vaccinated intramuscularly with adjuvanted HPAI vaccine, non-adjuvanted HPAI 
vaccine, or saline.  Mice were challenged intranasally 7 weeks later with 10pfu 
A/Vietnam/1203/2004. A. Percent bodyweight change in surviving mice treated 
with the adjuvanted HPAI vaccine (triangles), non-adjuvanted HPAI vaccine 
(squares), or saline (diamonds). Non-challenged controls are represented by 
circles. Percent bodyweight change is expressed as mean ± SEM (p<.0001, one-
way repeated measures ANOVA comparing all groups). B. Kaplan-Meier survival 
curve for mice treated with adjuvanted HPAI vaccine (dotted line), non-
adjuvanted HPAI vaccine (solid line), or saline (short dashed line). Non-
challenged controls are represented by the long dashed line (p<.05, Gehan-
Breslow Wilcoxon test comparing all groups).   
 
Figure 2. Neutralizing antibody titers were increased in BALB/c mice 
following vaccination with adjuvanted HPAI vaccine. BALB/c mice (n=6 per 
group) were given a primary, or a primary and secondary, intramuscular injection 
of the HPAI vaccine with or without alum adjuvant. Sera were collected 7 weeks 
following primary vaccination and evaluated by neutralization assay. A. 
Neutralizing antibody titers in mice following a primary vaccination of adjuvanted 
HPAI vaccine (squares) or non-adjuvanted HPAI vaccine (circles). Error bars 
indicated mean ± SEM (*p<.05, Student’s t-test). B. Neutralizing antibody titers in 
91 
 
mice following a primary and secondary vaccination with adjuvanted HPAI 
vaccine (circles) or non-adjuvanted HPAI vaccine (squares). Error bars indicated 
mean ± SEM (*p<.05, Student’s t-test). 
 
Figure 3. Expression of co-stimulatory molecules was increased on BMDCs 
treated with adjuvanted HPAI vaccine. BMDCs were treated overnight at 37°C 
with media alone, adjuvanted HPAI vaccine, or non-adjuvanted HPAI vaccine.  
Following incubation, cells were collected and stained for co-stimulatory markers 
and analyzed by flow cytometry. A-C. Expression of CD40 (A), CD86 (B), and 
MHC II (C) on BMDCs treated with adjuvanted HPAI vaccine (dotted line), non-
adjuvanted HPAI vaccine (solid line), or media alone (shaded area) depicted by 
histograms showing fluorescence intensity. Similar results were obtained from 
three independent experiments. D-F. Bar graphs illustrating percent positive of 
BMDCs treated with adjuvanted vaccine (checkered bars), non-adjuvanted 
vaccine (white bars), or media alone (black bars) expressing CD40 (D), CD86 
(E), and MHC II (F). Error bars represent mean ±SEM (*p<.05, **p<.005, 
Student’s t-test). Results were obtained from three independent experiments. 
 
Figure 4. Neither vaccine induced cytokine production by BMDCs. BMDCs 
were treated overnight at 37°C with media alone, adjuvanted HPAI vaccine, non-
adjuvanted HPAI vaccine, LPS, or LPS + ATP. Cytokine expression was 
assessed by ELISA.  A. IL-1β secretion by BMDCs treated with media alone 
(black bars), LPS + ATP (diagonal bars), adjuvanted HPAI vaccine (checkered 
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bars), or non-adjuvanted vaccine (white bars). Error bars represent mean ± SEM. 
B-D. Production of IL-6 (B), IL-12 (C), and TNF-α by BMDCs treated with media 
alone (black bars), LPS (striped bars), adjuvanted HPAI vaccine (checkered 
bars), or non-adjuvanted HPAI vaccine (white bars). Error bars represent mean ± 
SEM. Results represent three independent experiments.    
 
Figure 5. BMDCs treated with adjuvanted HPAI vaccine demonstrated 
increased antigen uptake. BMDCs were treated with FITC conjugated 
adjuvanted or non-adjuvanted HPAI vaccine for 2 hours at 37°C and then 
analyzed for FITC expression. A. Histogram depicting fluorescence intensity of 
BMDCs treated with adjuvanted HPAI vaccine conjugated to FITC (solid line) or 
non-adjuvanted HPAI vaccine conjugated to FITC (dotted line) analyzed by flow 
cytometry. Shaded area represents a non-stained control. B. Median 
fluorescence intensity (MFI), expressed as the mean ± SEM (log10), in BMDCs 
treated with adjuvanted HPAI vaccine conjugated to FITC (checkered bar) or 
non-adjuvanted HPAI vaccine conjugated to FITC (white bar) as determined by 
flow cytometry. The black bar represents a non-stained control (*p<.05, Student’s 
t-test). Results were obtained from three independent experiments.  C. 
Fluorescence microscopy of BMDCs treated with either the adjuvanted or non-
adjuvanted HPAI vaccines conjugated to FITC. CD11c conjugated to PE-Cy7 
was used as a cell surface marker.  
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Figure 6. Intracellular processing is increased in BMDCs treated with 
adjuvanted HPAI vaccine. BMDCs were pre-treated with acridine orange for 
15min at 37°C followed by treatment overnight with adjuvanted or non-
adjuvanted HPAI vaccine. A. Histogram depicting fluorescence intensity of 
BMDCs pre-treated with acridine orange followed by treatment with adjuvanted 
HPAI vaccine (solid black line), non-adjuvanted HPAI vaccine (dotted line), alum 
(solid grey line), or acridine orange alone (dashed line) analyzed by flow 
cytometry. The shaded area represents a non-stained control. B.  Median 
acridine orange fluorescence (MFI), expressed as the mean ± SEM (log10) in 
BMDCs treated with media alone (black bars), acridine orange alone 
(crisscrossed bar), alum (dotted bar), adjuvanted HPAI vaccine (checkered bar), 
or non-adjuvanted HPAI vaccine (white bar) (*p<.05, Student’s t-test). Results 
were obtained from 3 independent experiments. C. Fluorescence microscopy of 
BMDCs pre-treated with acridine orange followed by treatment with either the 
adjuvanted or non-adjuvanted HPAI vaccine.  
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CHAPTER FOUR: DISCUSSION 
Summary of Studies 
The purpose of these studies was to further our understanding of the 
immunological mechanisms of vaccination, specifically with regard to inactivated 
split virion subunit vaccines targeting influenza viruses. More precisely, the aims 
of these studies were to identify mechanisms by which the seasonal and 
adjuvanted H5N1 vaccines elicited a protective immune response, whereas the 
non-adjuvanted H5N1 vaccine produced attenuated immunogenicity. Specifically, 
these studies investigated the ability of the vaccines to activate APCs, induce the 
production of neutralizing antibodies, and provide protection following lethal 
challenge in a BALB/c mouse model. A more complete understanding of the 
mechanisms of vaccination will lead to the development of more effective 
vaccines, and the studies presented herein provide insight into the improvement 
of vaccines targeting HPAI.  
The immune response to subunit vaccines targeting seasonal influenza 
and HPAI were examined utilizing both in vivo and in vitro experimental 
approaches (Chapter 2). The seasonal and H5N1 vaccines were developed 
using the same manufacturing process, but have shown disparate efficacies in 
clinical trials. Regardless of the route of administration (SC or IM), the seasonal 
vaccine demonstrated immunogenicity, whereas H5N1 vaccination did not result 
in the production of detectable levels of neutralizing antibodies (Chapter 2, Figure 
1). These findings validate the mouse model established herein as a suitable 
model for studying the immune response to influenza vaccination as vaccine 
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efficacy in the mouse model was comparable to that seen in humans. Studies 
conducted in vitro evaluated APC activation, and demonstrated an increase in 
the ability of the seasonal vaccine to activate DCs when compared to the H5N1 
vaccine (Chapter 2, Figure 2). Neither vaccine stimulated TLRs or NLRs 
(Chapter 2, Figure 3), and this finding led to the investigation of the involvement 
of CLRs. For the first time, to our knowledge, this study demonstrates a role for 
CLRs in the immune response to vaccination against influenza (Chapter 2, 
Figures 4 and 5), and the ability of the H5N1 vaccine to bind CLRs but not initiate 
a signaling cascade provides an explanation for the attenuated response to 
H5N1 vaccination (Chapter 2, Figure 6). 
In Chapter 3, the role of alum in the immune response to the H5N1 
influenza subunit vaccine was evaluated in a lethal challenge mouse model of 
infection. When compared to the non-adjuvanted H5N1 vaccine, treatment with 
the vaccine plus alum resulted in increased immunogenicity (Chapter 3, Figure 2) 
and decreased morbidity and mortality (Chapter 3, Figure 1). In vitro, the 
adjuvanted H5N1 vaccine more efficiently activated APCs (Chapter 3, Figure 3); 
however, neither vaccine induced the production of pro-inflammatory cytokines. 
The absence of cytokine secretion suggests that neither the activation of PRRs, 
nor the NLRP3 inflammasome, is involved in the mechanism of action of alum in 
our model (Chapter 3, Figure 4). Herein, alum functions as an adjuvant by 
facilitating increased antigen uptake and intracellular processing (Chapter 3, 
Figures 5 and 6), and while alum rescues the efficacy of the H5N1 vaccine, it 
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does so through a different mechanism of action than that utilized by seasonal 
influenza vaccines. 
 
Limitations of the Studies 
Animal models are essential for the study of infectious diseases, as it can 
be difficult and unethical to study these diseases in humans. Mice are a favorable 
model in which to study immunology due to low cost, the broad availability of 
immunological reagents, and transgenic strains [1, 2]. In addition, laboratory mice 
are inbred and genetically identical, which facilitates reproducibility of 
experimental results [3]. Despite these benefits, pathogens such as influenza do 
not naturally infect mice, and thus limit their relevance [1, 2], and the inbred 
nature of laboratory mice does not reflect the genetic diversity and variability 
present in the human population [3]. Additionally, while studies conducted in 
animal models provide invaluable insight into human biological processes, 
differences in the correlates of protection between animals and humans may lead 
to results obtained in an animal model that are not a true representation of the 
human immune response [4, 5].   
Another limitation of the current studies is that while vaccine 
immunogenicity was assessed in vivo, APC activation and the mechanisms 
leading to this activation were evaluated in vitro. As APC:T cell interactions can 
be influenced by the lymph node micro-environment, the addition of in vivo 
experiments evaluating APC activation and migration, antigen presentation to T 
cells, and T cell activation would validate the findings presented herein.  
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Additionally, data demonstrating APC:T cell interactions in vitro are not 
included in the current studies. Experiments were conducted to assess antigen 
presentation by BMDCs to T cells in vitro, yet these experiments were 
unsuccessful. Ideally, T cells from transgenic mice specific for the VN1203 HA 
protein would be utilized; however, such mice are not available. In an attempt to 
overcome this limitation, T cells were harvested from the spleens of mice 
vaccinated with either the seasonal or non-adjuvanted HPAI vaccines three 
weeks following vaccination. BMDCs pulsed with the seasonal or non-adjuvanted 
HPAI vaccine for 24 hours were co-cultured with T cells harvested from the 
vaccinated mice for three days. T cell activation was assessed by cell 
proliferation assays, but no T cell proliferation was detected.  
An additional limitation of the studies presented herein is that the seasonal 
influenza vaccine evaluated in the current studies is trivalent whereas the H5N1 
vaccine is monovalent. The trivalent nature of the seasonal vaccine may affect its 
immunogenic properties; therefore, examination of the immune response to an 
efficacious monovalent subunit influenza vaccine, such as the 2009 H1N1 
pandemic vaccine, would expand upon and strengthen the current studies.  
 
Future Directions 
The findings presented herein provide insight into a possible mechanism 
for the attenuated function of the H5N1 vaccine. As mentioned in the limitations 
section above, in vivo studies examining APC activation and migration, antigen 
presentation to T cells, and subsequent T cell activation would expand on the 
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current results. Draining lymph nodes should be harvested following vaccination 
and assessed for cell populations and the frequencies of those populations. 
Types and numbers of APCs should be identified and assessed for the 
expression of co-stimulatory molecules such as CD40, CD80, and CD86, as well 
as MHC I/II. The use of fluorescently labeled vaccines may help to identify APCs 
that respond to antigen at the site of vaccination and then travel to the draining 
lymph nodes; however, an increase in the presence of APCs alone in the 
draining lymph nodes should indicate a response specific to vaccination. The 
frequency of CD4+ and CD8+ T cells should also be assessed as their numbers 
should be significantly higher in the lymph nodes of mice responding to 
vaccination due to T cell activation and clonal expansion. Assessment of a 
vaccine specific T cell response could be measured with the development and 
use of fluorescent tetramers that target the HA or NA proteins from the specific 
viruses used in the vaccines.     
The current studies propose a role for C-type lectin receptors in the 
immune response to influenza vaccination.  Future studies would expand on the 
involvement of CLR signaling and aim to identify the specific CLRs involved in 
influenza vaccine recognition. Assays determining total phosphorylation should 
be utilized as an indication for a general increase in signaling; however, these 
assays would not be specific to signaling downstream of CLRs, therefore the 
phosphorylation of specific CLR pathway components should be assessed. For 
example, ligand binding to the CLRs Dectin-1, Dectin-2, and Mincle induces 
receptor aggregation and initiates signaling through the immunoreceptor 
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tyrosine-based activation motif (ITAM) on the receptors or FcRγ. Tyrosine 
residues on the ITAMs are phosphorylated by Src family kinases and lead to the 
recruitment and activation of the kinase Syk [6]; therefore, the expression of 
phosphorylated Syk could be analyzed using western blot, or an inhibitor of Syk, 
such as piceatannol could be employed. Downstream of Syk is a protein complex 
consisting of CARD9, BCL10, and MALT1 (CBM), so activation of this CBM 
complex could also be assessed by western blot or the utilization of BCL10 
knockout mice [6, 7]. Raf-1 is another signaling component downstream of 
Dectin-1, and its activation could also be assessed [6]. 
In addition to the analysis of the activation of signaling components 
downstream of CLRs, the involvement of specific CLRs should be assessed. This 
could be accomplished by using antibodies against specific CLRs that would 
neutralize the receptors, blocking cellular activation. The utilization of short 
hairpin RNAs (shRNAs) that silence CLR genes through RNA interference 
(RNAi) could also be used to determine the involvement of specific CLRs [8, 9].  
While the current studies aimed to identify variations in the immune 
response to the seasonal and H5N1 vaccines, variations in the immune response 
ultimately result from differences in the target viruses. The ability of the seasonal 
influenza vaccine to activate C-type lectin receptors suggests that carbohydrate 
structures on the HA and NA antigens are essential for vaccine antigen 
recognition by these receptors. Differences in N-linked glycosylation sites on the 
target viruses may account for the ability of the seasonal vaccine to activate 
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signaling cascades whereas the H5N1 vaccine bound the receptors but did not 
initiate signaling.  
Glycosylation sites are determined by the amino acid sequence motif N-X-
T/S where X is any amino acid except proline [10, 11]. Previous studies have 
determined the glycosylation sites on the viruses used in the vaccines studied 
herein. The HA protein of A/Brisbane/10/2007, the H3N2 virus used in the 
2009/2010 seasonal influenza vaccine, has potential glycosylation sites at amino 
acid residues 63, 122, 126, 133, 144, and 165 [11]. The possible glycosylated 
residues on the HA protein of A/Brisbane/59/2007, the H1N1 virus used in the 
2009/2010 seasonal influenza vaccine, are at amino acid residues 15, 27, 58, 91, 
129, 163, and 290 [12]. The HA protein of A/Vietnam/1203/2004 (VN1203), the 
virus used in the H5N1 vaccine, has potential glycosylated positions at residues 
22, 34, 158, 165, 176, 204, 297, 495, and 555 [10, 13]. The glycosylation site at 
158 on VN1203 has been previously shown to decrease the antigenicity and 
immunogenicity of a live attenuated H5N1 vaccine studied in ferrets [13]. Future 
studies should aim to identify whether the addition or removal of glycosylation 
affects the ability of the influenza vaccines to bind and activate CLRs, and would 
determine the viral motifs recognized by the receptors. Motif recognition could 
also be examined utilizing viral peptide arrays and assessing CLR activation 
following treatment with peptides.   
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Conclusions 
Highly pathogenic avian influenza is an emerging infectious virus with the 
potential to cause a pandemic, and cases of both H5N1 and H7N9 are currently 
circulating in humans. The first study described in this dissertation compared the 
immune response to inactivated subunit vaccines targeting seasonal and H5N1 
influenza viruses, as well as, defined a mechanism for the attenuated response 
to the H5N1 vaccine. We conclude that seasonal influenza vaccines stimulate 
CLRs, implicating a novel role for CLRs in influenza vaccination, whereas the 
H5N1 vaccine binds to CLRs but does not initiate an immune response. 
The second study compared the immune response to the H5N1 vaccine 
with and without the addition of an alum adjuvant; studies were also performed to 
determine a mechanism of action for alum in our model of vaccination. We 
conclude that alum increases antigen uptake and intracellular processing. While 
the alum adjuvant is able to rescue the immunogenicity of the H5N1 vaccine, it 
does so though a different mechanism of activation than that employed by 
seasonal influenza vaccines. 
The development of vaccines for use against HPAI is a high priority, 
especially in affected countries, and there are many challenges concerning the 
development of pandemic influenza vaccines targeting HPAI. For example, the 
amount of vaccine that can be generated globally is limited and would be 
insufficient for complete coverage of the world’s population [14, 15]. Additionally, 
vaccine production capabilities are concentrated in industrialized countries, and it 
is estimated that deaths associated with an influenza pandemic will be greater in 
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developing countries than in industrialized countries due to factors such as: lack 
of access to adequate medical care; poor public health infrastructures; social 
factors  such as population density and housing conditions; and host factors such 
as poor nutrition and co-existing medical conditions like HIV/AIDS [15]. 
Furthermore, it is not possible to predict which subtype of influenza will cause the 
next pandemic, so a vaccine stockpiled against H5N1 may not protect against an 
outbreak of H7N9 [16]. The production of a vaccine following the identification of 
a virus causing a pandemic is time consuming, and conventional methods used 
for growing the virus for the vaccine strain may not be sufficient as HPAI viruses 
are difficult to grow in eggs [14, 17]. Finally, the low immunogenicity produced by 
current HPAI pandemic vaccines demonstrates a necessity for multiple 
vaccinations, or the addition of an adjuvant, in order to provide protection [14, 18, 
19]. A greater understanding behind the immunological mechanisms of influenza 
vaccination will lead to the development of more effective vaccines, and will help 
to overcome one of the challenges facing pandemic HPAI vaccine development. 
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APPENDIX A 
Results 
Development of cross-protective neutralizing antibodies 
 One challenge facing the development of vaccines targeting HPAI is that a 
vaccine developed which is specific to the virus circulating at the time, such as 
the H5N1 vaccine targeting VN1203 developed in 2003/2004, may not provide 
protection to a different strain of HPAI that circulates in the future, such as the 
H7N9 HPAI virus that began circulating in February 2013, or even a different 
strain of H5N1. Studies were conducted to determine whether mice vaccinated 
with the adjuvanted H5N1 vaccine targeting VN1203 developed cross-protective 
neutralizing antibodies against other strains of H5N1. Sera from BALB/c mice 
vaccinated with the adjuvanted H5N1 vaccine, which produced neutralizing 
antibodies against VN1203, were tested for the ability to neutralize other H5N1 
viruses, specifically: the clade 0 viruses A/Hong Kong/156/1997 (HK156), 
A/Hong Kong/483/1997 (HK483), and A/Hong Kong/486/1997; the clade 1 virus 
A/Vietnam/1194/2004 (VN1194); and the clade 2 viruses 
A/duck/Hunan/795/2002 (DH795) and A/common magpie/Hong Kong/645/2006 
(CM645). Briefly, six to eight-week-old BALB/c mice received either a primary or 
a primary and secondary vaccination of the adjuvanted H5N1 vaccine with doses 
ranging from 0.6ug to 30ug. Secondary vaccinations occurred three weeks 
following primary vaccinations. Sera were collected three weeks following 
primary vaccination or four weeks following secondary vaccination and assessed 
for neutralizing antibodies using a neutralization assay. Sera from two of three 
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mice tested against HK156 and HK486 contained neutralizing antibody titers 
greater than 1:40, and sera from one of three mice tested against HK483 
contained neutralizing antibody titers greater than 1:40. Sera from three of three 
mice tested against VN1194, DH795, and CM645 contained neutralizing 
antibodies greater than 1:40 (Figure A1). This data demonstrates that mice 
vaccinated against VN1203 produced cross-protective neutralizing antibodies 
against other strains of H5N1.   
 
Antigen presenting cell migration following influenza vaccination in vivo 
 The mechanisms surrounding APC activation by inactivated influenza 
subunit vaccines presented in the body of this work were elucidated in vitro. 
Preliminary studies analyzing APC activation in vivo were also conducted. To 
determine the main APC type responding to influenza vaccination in vivo, six to 
eight-week-old BALB/c mice (n = 1 per treatment per time point) were vaccinated 
subcutaneously (SC) in the inguinal area with either the seasonal or non-
adjuvanted HPAI vaccine with or without the addition of a 1:10 dilution of FITC+ 
FluoSpheres. DCs and macrophages expressing FITC were considered to have 
internalized vaccine antigen. Popliteal lymph nodes were harvested 24 or 48 
hours following vaccination and assessed for the quantity of DCs and 
macrophages present therein. DCs were identified as CD11c+ /CD11b+, and 
macrophages were identified as CD11c+/F4/80+ using flow cytometry. Following 
vaccination with either the seasonal or non-adjuvanted HPAI vaccines with the 
addition of FITC+ FluoSpheres, a larger number of total and FITC+ DCs was 
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found in the draining lymph node (DLN) compared to macrophages (Figure A2a 
and c). The results also demonstrated that a larger number of DCs may be 
responding to the seasonal vaccine compared to the HPAI vaccine. Additionally, 
an increased quantity of total and FITC+ DCs was present in the DLN 24 hours 
following vaccination compared to 48 hours following vaccination (Figure A2b 
and d). These data suggest that DCs are the primary APCs responding to 
influenza vaccination, and that 24 hours is the better time point at which to 
analyze APC activity in the DLN.  
In the experiment discussed above, the majority of cells isolated from the 
DLN at 24 hours following vaccination with either the seasonal or non-adjuvanted 
HPAI vaccine expressed FITC (Figure A3). Interestingly, 48 hours following 
vaccination, a much larger FITC negative cell population was present in the DLN 
of mice vaccinated with the seasonal vaccine compared to mice vaccinated with 
the non-adjuvanted HPAI vaccine. In the DLN of mice that received the non-
adjuvanted HPAI vaccine, there remained a larger number of FITC+ cells 
compared to mice that received the seasonal vaccine. This data suggests that 48 
hours following vaccination, in mice treated with the seasonal vaccine, APCs 
have presented antigen to T cells and T cells are clonally expanding. However, a 
limitation to this study is that T cell markers were not utilized, so this conclusion 
is only speculation at this time and needs follow-up.   
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Antigen presenting cell activation in vivo 
To further examine APC activation in vivo, expression of the co-
stimulatory molecules CD40 and CD86 on DCs harvested from the popliteal 
lymph node was assessed. BALB/c mice (n = 3 per treatment) were vaccinated 
intramuscularly (IM) with either the seasonal or non-adjuvanted H5N1 vaccine. 
Popliteal lymph nodes were harvested 24 hours following vaccination and 
expression of the co-stimulatory molecules CD40 and CD86 was assessed by 
flow cytometry. DCs were identified as CD11c/CD11b positive. Significantly 
higher levels of CD40 (Figure A4a) and CD86 (Figure A4b) were detected on 
DCs isolated from mice that received the seasonal vaccine compared to mice 
that received the non-adjuvanted HPAI vaccine. These data demonstrate that the 
seasonal vaccine is able to more efficiently activate APCs in vivo compared to 
the non-adjuvanted HPAI vaccine. Interestingly, when comparing cell counts, the 
number of DCs present in the DLN did not vary between treatment groups as 
seen in Figure A2 (data not shown). This could be due to the difference in the 
route of immunization (IM vs. SC).    
 
T cell responses in vivo 
 Preliminary studies assessed early T cell responses in vivo. BALB/c mice 
(n = 2 per treatment) were vaccinated SC in the inguinal area with either the 
inactivated subunit vaccine targeting the 2009 H1N1 pandemic virus or the non-
adjuvanted HPAI vaccine. Popliteal lymph nodes were harvested 24 hours 
following vaccination and assessed for a CD28-/CD62L+ homing T cell 
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population. In the DLNs harvested from mice that received the 2009 H1N1 
vaccine, a CD28-/CD62L+ homing T cell population was detected, whereas in 
mice that received the non-adjuvanted HPAI vaccine, this cell population was not 
detected (Figure A5). This data suggests differences in T cell responses to the 
2009 H1N1 vaccine when compared to the non-adjuvanted HPAI vaccine.               
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Figure Legends 
Figure A1. Cross-protective neutralizing antibodies in BALB/c mice. BALB/c 
mice received either a primary or a primary and secondary vaccination of the 
adjuvanted HPAI vaccine targeting VN1203. Sera were collected three weeks 
following primary vaccination or four weeks following secondary vaccination and 
neutralizing antibody titers to other strains of H5N1 were determined utilizing 
neutralization assays. The viruses analyzed include: HK156 (closed circles); 
HK483 (squares); HK486 (triangles); VN1194 (upside-down triangles); DH795 
(diamonds); and CM645 (open circles). Data points represent individual animals.   
 
Figure A2. DCs respond to influenza vaccine antigen in vivo. BALB/c mice 
received a SC vaccination of either the seasonal or non-adjuvanted HPAI 
vaccine with or without the addition of FITC+ FluoSpheres. Popliteal lymph nodes 
were harvested 24 or 48 hours following vaccination and assessed for 
CD11c+/CD11b+ DC and CD11c+/F4/80+ macrophage populations by flow 
cytometry. A and B. Cell counts in the DLN following vaccination with either the 
seasonal vaccine (white bars) or non-adjuvanted HPAI vaccine (black bars) at 24 
and 48 hours respectively. C and D. Cell counts representing FITC+ APCs in the 
DLN following vaccination with seasonal vaccine (white bars) or non-adjuvanted 
HPAI vaccine (black bars) mixed with FITC+ FluoSpheres at 24 and 48 hours 
respectively. The mice utilized in this experiment were separate from those in A 
and B.  
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Figure A3. Increased FITC negative cell population present in the DLN 
following seasonal vaccination.  BALB/c mice received a SC vaccination of 
either the seasonal or non-adjuvanted HPAI vaccine with the addition of FITC+ 
FluoSpheres. Popliteal lymph nodes were harvested 24 or 48 hours following 
vaccination and cells were assessed for the presence or absence of FITC+ 
expression by flow cytometry. 
 
Figure A4. Increased expression of co-stimulatory molecules on DCs 
treated with seasonal influenza vaccine. BALB/c mice were vaccinated 
intramuscularly with either the seasonal vaccine or non-adjuvanted HPAI 
vaccine. Popliteal lymph nodes were harvested 24 hours following vaccination 
and CD11c+/CD11b+ DCs were assessed for the expression of co-stimulatory 
markers by flow cytometry. A. Median fluorescence intensity (MFI) of CD40 
expression on DCs isolated from the DLNs of mice vaccinated with the seasonal 
influenza vaccine (white bars) or non-adjuvanted HPAI vaccine (black bars). 
Error bars indicate mean ± SEM (*p<.05, Student’s t-test). B. Median 
fluorescence intensity (MFI) of CD86 expression on DCs isolated from the DLNs 
of mice vaccinated with the seasonal influenza vaccine (white bars) or non-
adjuvanted HPAI vaccine (black bars). Error bars indicate mean ± SEM (*p<.05, 
Student’s t-test).  
 
Figure A5. CD28-/CD62L+ homing T cell population present in the DLN of 
mice treated with seasonal but not HPAI vaccine. BALB/c mice were 
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vaccinated subcutaneously with either the 2009 H1N1 pandemic vaccine or the 
non-adjuvanted HPAI vaccine. Popliteal lymph nodes were harvested 24 hours 
following vaccination and cell populations were assessed by flow cytometry for 
CD28-/CD62L+ homing T cells. Cells were gated on CD28- cell populations 
followed by expression of CD62L.    
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